{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "#import required libraries for webscraping using selenium\n",
    "from selenium import webdriver\n",
    "from selenium.webdriver.common.keys import Keys\n",
    "from selenium.webdriver.support.ui import Select\n",
    "from selenium.webdriver.support.ui import WebDriverWait\n",
    "from selenium.common.exceptions import NoSuchElementException\n",
    "from selenium.webdriver.common.by import By\n",
    "from selenium.webdriver.support import expected_conditions as EC\n",
    "import time\n",
    "import os\n",
    "import requests\n",
    "from tabula.io import read_pdf\n",
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# write a python code to extract link from following webpage https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/pbac-outcomes (do not give previous suggestion)\n",
    "url = \"https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/pbac-outcomes\"\n",
    "driver = webdriver.Chrome(executable_path=r\"E:/Usecases/Webscrape/chromedriver.exe\")\n",
    "driver.get(url)\n",
    "outcome_list =[] \n",
    "outcome_links = driver.find_elements_by_xpath('//*[@id=\"1.1251\"]/ul[1]/li')\n",
    "for link in outcome_links:\n",
    "    outcome_list.append(link.find_elements_by_tag_name(\"a\")[0].get_attribute(\"href\"))\n",
    "# driver.close()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "inner_links = []\n",
    "for link in outcome_list:\n",
    "    driver.get(link)\n",
    "    # time.sleep(2)\n",
    "    links = driver.find_elements_by_xpath('//*[@id=\"2\"]/ul/li')\n",
    "    inner_link_temp = []\n",
    "    for inner_link in links:\n",
    "        inner_link_temp.append(inner_link.find_elements_by_tag_name(\"a\")[0].get_attribute(\"href\"))\n",
    "    inner_links.append(inner_link_temp)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "inner_links"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "df_list = []\n",
    "for item in outcome_list:\n",
    "    if item.endswith(\".pdf\"):\n",
    "        file_name = item.split(\"/\")[-1]\n",
    "        pdf_response = requests.get(item)\n",
    "        with open(\"./Download/\"+file_name, \"wb\") as f:\n",
    "            f.write(pdf_response.content)\n",
    "        print(f\"Downloaded {file_name} from {item}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#iterate all files in the folder and extract table from each pdf file\n",
    "for file in os.listdir(\"./Download\"):\n",
    "    if file.endswith(\".pdf\"):\n",
    "        df_list.append(read_pdf(\"./Download/\"+file, pages=\"all\", multiple_tables=True, pandas_options={'header': None}))\n",
    "        print(f\"Extracted table from {file}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#write function to extract table from pdf file without using tabula\n",
    "def extract_table(pdf_file):\n",
    "    # Use tabula to read the PDF file and extract the table\n",
    "    table = tabula.read_pdf(pdf_file, pages=\"all\")\n",
    "    # Return the table as a pandas dataframe\n",
    "    return table\n",
    "#write another function with diffrent approach using camelot\n",
    "def extract_table_camelot(pdf_file):\n",
    "    # Use tabula to read the PDF file and extract the table\n",
    "    tables = camelot.read_pdf(pdf_file, pages=\"all\")\n",
    "    # Return the table as a pandas dataframe\n",
    "    return tables\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Write a function to anagram of a string\n",
    "def anagram(string1, string2):\n",
    "    # Write your code here\n",
    "    if len(string1) != len(string2):\n",
    "        return False\n",
    "    else:\n",
    "        string1 = string1.lower()\n",
    "        string2 = string2.lower()\n",
    "        for char in string1:\n",
    "            if char in string2:\n",
    "                string2 = string2.replace(char, \"\", 1)\n",
    "            else:\n",
    "                return False\n",
    "        return True\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Write python code to find seasonal index of a given data\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "import matplotlib.pyplot as plt\n",
    "from statsmodels.tsa.seasonal import seasonal_decompose\n",
    "from statsmodels.tsa.stattools import adfuller\n",
    "from statsmodels.graphics.tsaplots import plot_acf, plot_pacf\n",
    "from statsmodels.tsa.arima_model import ARIMA\n",
    "\n",
    "# Read the data\n",
    "df = pd.read_csv(\"https://raw.githubusercontent.com/rajeevratan84/datascienceforbusiness/master/monthly_milk_production.csv\")\n",
    "df.head()\n",
    "\n",
    "# Convert the date column to datetime format\n",
    "df['Month'] = pd.to_datetime(df['Month'])\n",
    "\n",
    "# Set the date column as index\n",
    "df.set_index('Month', inplace=True)\n",
    "\n",
    "# Plot the data\n",
    "df.plot(figsize=(12, 6))\n",
    "plt.show()\n",
    "\n",
    "# Decompose the data\n",
    "decomposition = seasonal_decompose(df, model='additive')\n",
    "decomposition.plot()\n",
    "plt.show()\n",
    "\n",
    "# Check for stationarity\n",
    "result = adfuller(df['Production'])\n",
    "print('ADF Statistic: {}'.format(result[0]))\n",
    "print('p-value: {}'.format(result[1]))\n",
    "\n",
    "# Plot the ACF and PACF plots\n",
    "plot_acf(df, lags=20)\n",
    "plot_pacf(df, lags=20)\n",
    "plt.show()\n",
    "\n",
    "# Split the data into train and test\n",
    "train = df[:156]\n",
    "test = df[156:]\n",
    "\n",
    "# Build the model\n",
    "model = ARIMA(train, order=(1, 1, 1))\n",
    "model_fit = model.fit()\n",
    "\n",
    "# Predict the values\n",
    "predictions = model_fit.forecast(steps=12)[0]\n",
    "\n",
    "# Plot the predictions\n",
    "plt.plot(test)\n",
    "plt.plot(predictions, color='red')\n",
    "plt.show()\n",
    "\n",
    "#calculate accuracy of the model\n",
    "from sklearn.metrics import mean_squared_error\n",
    "from math import sqrt\n",
    "\n",
    "rmse = sqrt(mean_squared_error(test, predictions))\n",
    "print(rmse)\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#write a python function to calculate \"seasonality index\" by quarter\n",
    "def seasonality_index(df):\n",
    "    # Write your code here\n",
    "    df['Month'] = pd.to_datetime(df['Month'])\n",
    "    df.set_index('Month', inplace=True)\n",
    "    decomposition = seasonal_decompose(df, model='additive')\n",
    "    return decomposition.seasonal.groupby(decomposition.seasonal.index.quarter).mean()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from pdfminer.pdfparser import PDFParser\n",
    "from pdfminer.pdfdocument import PDFDocument\n",
    "from pdfminer.pdfinterp import PDFResourceManager, PDFPageInterpreter\n",
    "from pdfminer.converter import XMLConverter\n",
    "from pdfminer.layout import LAParams\n",
    "from pdfminer.pdfpage import PDFPage\n",
    "from io import BytesIO\n",
    "\n",
    "# Path to your PDF file\n",
    "pdf_file = 'path/to/your/pdf/file.pdf'\n",
    "\n",
    "# Path to the output XML file\n",
    "xml_file = 'path/to/output/xml/file.xml'\n",
    "\n",
    "# Open the PDF file in binary mode\n",
    "with open(pdf_file, 'rb') as fp:\n",
    "    # Create a PDF parser object\n",
    "    parser = PDFParser(fp)\n",
    "    # Create a PDF document object\n",
    "    document = PDFDocument(parser)\n",
    "\n",
    "    # Create a PDF resource manager object\n",
    "    rsrcmgr = PDFResourceManager()\n",
    "\n",
    "    # Create a BytesIO object to store the XML output\n",
    "    xml_data = BytesIO()\n",
    "\n",
    "    # Set up parameters for the XML converter\n",
    "    laparams = LAParams()\n",
    "\n",
    "    # Create a PDF to XML converter object\n",
    "    converter = XMLConverter(rsrcmgr, xml_data, laparams=laparams)\n",
    "\n",
    "    # Create a PDF interpreter object\n",
    "    interpreter = PDFPageInterpreter(rsrcmgr, converter)\n",
    "\n",
    "    # Iterate over each page in the PDF document\n",
    "    for page in PDFPage.create_pages(document):\n",
    "        # Process the page\n",
    "        interpreter.process_page(page)\n",
    "\n",
    "    # Get the XML data from the BytesIO object\n",
    "    xml_data.seek(0)\n",
    "    xml_content = xml_data.read().decode()\n",
    "\n",
    "    # Write the XML content to the output file\n",
    "    with open(xml_file, 'w', encoding='utf-8') as xml_fp:\n",
    "        xml_fp.write(xml_content)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "import win32com.client\n",
    "import os\n",
    "\n",
    "def read_table(table):\n",
    "  \"\"\"Reads a table with vertically merged cells in Win32Com Word.\n",
    "\n",
    "  Args:\n",
    "    table: The table object to read.\n",
    "\n",
    "  Returns:\n",
    "    A list of lists, where each sublist represents a row in the table.\n",
    "  \"\"\"\n",
    "\n",
    "  rows = []\n",
    "  for row in table.Rows:\n",
    "    row_data = []\n",
    "    for cell in row.Cells:\n",
    "      if cell.MergedCells.Count > 0:\n",
    "        row_data.append(\"\")\n",
    "      else:\n",
    "        row_data.append(cell.Range.Text)\n",
    "    rows.append(row_data)\n",
    "  return rows\n",
    "\n",
    "# def main():\n",
    "#   \"\"\"Reads a table with vertically merged cells in Win32Com Word and prints it out.\"\"\"\n",
    "\n",
    "#   word = win32com.client.Dispatch(\"Word.Application\")\n",
    "#   doc = word.Documents.Open(\"my_document.docx\")\n",
    "#   table = doc.Tables(1)\n",
    "#   rows = read_table(table)\n",
    "#   for row in rows:\n",
    "#     print(row)\n",
    "\n",
    "# if __name__ == \"__main__\":\n",
    "#   main()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "word = win32com.client.Dispatch(\"Word.Application\")\n",
    "doc = word.Documents.Open(os.path.abspath(\"./Download/pbac-web-outcomes-11-2021-v2.docx\"))\n",
    "table = doc.Tables(1)\n",
    "# rows = read_table(table)\n",
    "# for row in rows:\n",
    "#     print(row)\n",
    "\n",
    "# word = win32com.client.Dispatch(\"Word.Application\")\n",
    "# doc = word.Documents.Open(\"MyDocument.docx\")\n",
    "# table = doc.Tables(\"Table1\")\n",
    "\n",
    "# for row in table.Rows:\n",
    "#     if row.MergeCells:\n",
    "#         row.Unmerge()\n",
    "\n",
    "# doc.Save()\n",
    "\n",
    "# for row in range(table.Rows.Count):\n",
    "#     for cell in table.Rows[row].Cells:\n",
    "#         value = cell.Value\n",
    "#         print(value)\n",
    "\n",
    "# doc.Save()\n",
    "\n",
    "for col in table.Columns:\n",
    "    if col.IsMerged:\n",
    "        col.Unmerge()\n",
    "doc.Save()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#resolve following issue \"com_error: (-2147352567, 'Exception occurred.', (0, 'Microsoft Word', 'Cannot access individual rows in this collection because the table has vertically merged cells.', 'wdmain11.chm', 25471, -2146822297), None)\"\n",
    "#https://stackoverflow.com/questions/64884102/how-to-read-table-with-vertically-merged-cells-in-win32com-word\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#write a python function to read a table with vertically merged cells in Win32Com Word\n",
    "import win32com.client\n",
    "import os\n",
    "\n",
    "def read_table(table):\n",
    "    \"\"\"Reads a table with vertically merged cells in Win32Com Word.\n",
    "    \n",
    "    Args:\n",
    "        table: The table object to read.\n",
    "    \n",
    "    Returns:\n",
    "        A list of lists, where each sublist represents a row in the table.\n",
    "    \"\"\"\n",
    "    \n",
    "    rows = []\n",
    "    for row in table.Rows:\n",
    "        row_data = []\n",
    "        for cell in row.Cells:\n",
    "            if cell.MergedCells.Count > 0:\n",
    "                row_data.append(\"\")\n",
    "            else:\n",
    "                row_data.append(cell.Range.Text)\n",
    "        rows.append(row_data)\n",
    "    return rows\n",
    "\n",
    "def main():\n",
    "    \"\"\"Reads a table with vertically merged cells in Win32Com Word and prints it out.\"\"\"\n",
    "    \n",
    "    word = win32com.client.Dispatch(\"Word.Application\")\n",
    "    doc = word.Documents.Open(\"my_document.docx\")\n",
    "    table = doc.Tables(1)\n",
    "    rows = read_table(table)\n",
    "    for row in rows:\n",
    "        print(row)\n",
    "\n",
    "#above function is not working\n",
    "#https://stackoverflow.com/questions/64884102/how-to-read-table-with-vertically-merged-cells-in-win32com-word"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#write a function to extract table from pdf using camelot\n",
    "import camelot\n",
    "tables = camelot.read_pdf('./Download/pbac-web-outcomes-11-2021-v2.pdf', flavor='stream')\n",
    "tables.export('foo.csv', f='csv', compress=True) # json, excel, html, sqlite\n",
    "tables[0].parsing_report\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "import cv2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "import subprocess\n",
    "import json\n",
    "import os\n",
    "\n",
    "\n",
    "def extract_tables_from_pdf(pdf_path):\n",
    "    try:\n",
    "        output = subprocess.check_output(['java', '-jar', 'pdfbox-app-2.0.29.jar', 'ExtractText', '-json', pdf_path], stderr=subprocess.STDOUT)\n",
    "        json_data = output.decode('utf-8')\n",
    "        extracted_tables = []\n",
    "\n",
    "        try:\n",
    "            data = json.loads(json_data)\n",
    "            pages = data['pages']\n",
    "\n",
    "            for page in pages:\n",
    "                tables = page['tables']\n",
    "                for table in tables:\n",
    "                    extracted_table = []\n",
    "                    rows = table['rows']\n",
    "                    for row in rows:\n",
    "                        cells = row['cells']\n",
    "                        extracted_row = [cell['text'] for cell in cells]\n",
    "                        extracted_table.append(extracted_row)\n",
    "                    extracted_tables.append(extracted_table)\n",
    "\n",
    "        except json.JSONDecodeError:\n",
    "            print('Error decoding JSON data.')\n",
    "\n",
    "        return extracted_tables\n",
    "\n",
    "    except subprocess.CalledProcessError as e:\n",
    "        print('Error running command: ', e.output.decode('utf-8'))\n",
    "        return None\n",
    "\n",
    "\n",
    "pdf_path = os.path.abspath('./Download/pbac-web-outcomes-11-2021-v2.pdf')\n",
    "tables = extract_tables_from_pdf(r\"E:\\Usecases\\Webscrape\\Download\\pbac-web-outcomes-11-2021-v2.pdf\")\n",
    "print(tables)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " <class 'str'>\n",
      "Error decoding JSON data.\n",
      "[]\n"
     ]
    }
   ],
   "source": [
    "import subprocess\n",
    "import json\n",
    "\n",
    "\n",
    "def extract_tables_from_pdf(pdf_path):\n",
    "    command = ['java', '-jar', 'pdfbox-app-2.0.26.jar', 'ExtractText', '-json', pdf_path]\n",
    "    process = subprocess.run(command, capture_output=True, text=True)\n",
    "    json_data = process.stdout\n",
    "    print(json_data, type(json_data))\n",
    "    extracted_tables = []\n",
    "\n",
    "    try:\n",
    "        data = json.loads(json_data)\n",
    "        pages = data['pages']\n",
    "\n",
    "        for page in pages:\n",
    "            tables = page['tables']\n",
    "            for table in tables:\n",
    "                extracted_table = []\n",
    "                rows = table['rows']\n",
    "                for row in rows:\n",
    "                    cells = row['cells']\n",
    "                    extracted_row = [cell['text'] for cell in cells]\n",
    "                    extracted_table.append(extracted_row)\n",
    "                extracted_tables.append(extracted_table)\n",
    "\n",
    "    except json.JSONDecodeError:\n",
    "        print('Error decoding JSON data.')\n",
    "\n",
    "    return extracted_tables\n",
    "\n",
    "pdf_path = os.path.abspath('./Download/pbac-web-outcomes-11-2021-v2.pdf')\n",
    "tables = extract_tables_from_pdf(\"./Download/pbac-web-outcomes-11-2021-v2.pdf\")\n",
    "print(tables)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[{'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'ABROCITINIB \\n\\nTablet 100 mg\\nTablet 200 mg\\n\\nCibinqo®\\n\\nPfizer Australia Pty Ltd\\n\\nCategory 2 submission\\n(New PBS listing) ', 'DRUG TYPE AND USE\\n': 'Atopic dermatitis', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a General Schedule Authority Required listing for the treatment of severe atopic dermatitis.', 'PBAC OUTCOME\\n': 'To be considered at a future PBAC meeting'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'ACALABRUTINIB \\n\\nCapsule 100 mg\\n\\nCalquence®\\n\\nAstraZeneca Pty Ltd\\n\\nStandard Re-entry submission\\n(Change to PBS listing) ', 'DRUG TYPE AND USE\\n': 'Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'Resubmission to request a General Schedule Authority Required listing for previously untreated CLL or SLL patients who are considered unsuitable for treatment with fludarabine-based chemoimmunotherapy, and unsuitable for venetoclax in combination with obinutuzumab, or who develop intolerance to venetoclax with obinutuzumab necessitating permanent treatment withdrawal.', 'PBAC OUTCOME\\n': 'The PBAC did not recommend the listing of acalabrutinib for the treatment of patients with previously untreated CLL or SLL, who are considered unsuitable for treatment with fludarabine-based chemoimmunotherapy and venetoclax + obinutuzumab, and for patients who permanently discontinue venetoclax + obinutuzumab due to intolerance.\\n\\nThe previous submission considered in July 2020 was for a broader population of CLL/SLL patients unsuitable for fludarabine-based chemotherapy. \\n\\nComparator: chlorambucil + obinutuzumab\\nThe PBAC agreed that this was the main comparator for the proposed population. However, the key clinical criteria for venetoclax + obinutuzumab unsuitability were subjective, and the PBAC recognised the issue that some patients/prescribers may prefer acalabrutinib as an oral therapy despite not being truly unsuitable for venetoclax + obinutuzumab. Based on the proposed PBS restriction, the PBAC considered venetoclax + obinutuzumab to be a relevant comparator. \\n\\nClinical claim: superior effectiveness and safety compared with chlorambucil + obinutuzumab\\nThe clinical claim was based on the ELEVATE-TN trial, previously considered by the PBAC in July 2020. The PBAC considered that a claim of superior comparative effectiveness was reasonable in relation to progression-free survival, noting the more mature data from the ELEVATE-TN trial in the resubmission with follow-up over approximately four years showed consistency of effect. At the same time, it remained of the view that overall survival data remained immature and there may not be a difference in overall survival over the longer term given subsequent lines of effective therapy are available. The PBAC considered that a superior safety claim was reasonable. \\n\\nEconomic claim: cost-utility versus chlorambucil + obinutuzumab\\nThe economic analysis was highly uncertain, and the incremental cost-effectiveness ratio was likely underestimated. A revised model, with a price reduction and reduced time horizon, would be required for PBAC decision making. Additionally, the sponsor would be required to provide further evidence that a proposed expenditure cap could be realised in practice, as this was critical to the resubmission’s cost-effectiveness estimates and financial impact.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'ACALABRUTINIB \\n\\nCapsule 100 mg\\n\\nCalquence®\\n\\nAstraZeneca Pty Ltd\\n\\nStandard Re-entry submission\\n(Change to PBS listing) ', 'DRUG TYPE AND USE\\n': 'Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'Resubmission to request a General Schedule Authority Required listing for previously untreated CLL or SLL patients who are considered unsuitable for treatment with fludarabine-based chemoimmunotherapy, and unsuitable for venetoclax in combination with obinutuzumab, or who develop intolerance to venetoclax with obinutuzumab necessitating permanent treatment withdrawal.', 'PBAC OUTCOME\\n': 'Sponsor’s comment: The sponsor had no comment.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'ADALIMUMAB\\n\\nInjection 40 mg in 0.8 mL pre-filled pen\\nInjection 40 mg in 0.8 mL pre-filled syringe\\n\\nHulio®\\n\\nAlphapharm Pty Ltd\\n\\nCategory 3 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Severe Crohn disease;\\nModerate to severe ulcerative colitis;\\nSevere active juvenile idiopathic \\narthritis;\\nComplex refractory fistulising Crohn \\ndisease;\\nSevere active rheumatoid arthritis;\\nSevere psoriatic arthritis;\\nAnkylosing spondylitis;\\nSevere chronic plaque psoriasis;\\nModerate to severe hidradenitis \\nsuppurativa.', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request listing of adalimumab biosimilar under the same conditions as its reference biologic.', 'PBAC OUTCOME\\n': 'The PBAC recommended the Authority Required listing of adalimumab (Hulio) in the form of 40 mg in 0.8 mL pre-filled syringe and pre-filled pen as a biosimilar brand of Humira®. The PBAC’s recommendation for listing was based on, among other matters, its assessment that the cost-effectiveness of Hulio would be acceptable if it were cost-minimised to Humira for the same indications. The PBAC advised that, Abrilada®, Amgevita®, Hadlima®, Hulio, Humira, Hyrimoz® and Idacio® PFS should be treated as equivalent to each other; and Abrilada, Amgevita, Hadlima, Hulio, Humira, Hyrimoz and Idacio PFP should be treated as equivalent to each other for the purpose of substitution.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'ADALIMUMAB\\n\\nInjection 80 mg in 0.8 mL pre-filled syringe\\n\\nHumira®\\n\\nAbbVie Pty Ltd\\n\\nCategory 4 submission\\n(Change to listing)\\n', 'DRUG TYPE AND USE\\n': 'Severe Crohn disease;\\nModerate to severe ulcerative colitis. ', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request General Schedule Authority Required listing of an additional strength of adalimumab as an induction dose for patients weighing less than 40 kg with Crohn disease or ulcerative colitis.', 'PBAC OUTCOME\\n': 'The PBAC recommended Authority Required listings of adalimumab 80 mg/0.8 mL pre-filled syringe (PFS) (1 pack) as an induction dose for patients with moderate to severe ulcerative colitis or severe Crohn disease weighing less than 40 kg on the basis of cost neutrality with the existing listings of adalimumab 40 mg PFS (2 pack). The PBAC accepted that availability of adalimumab 80 mg/0.8 mL PFS on the PBS will provide an alternative treatment course for this patient population in which patients will require only one 80\\xa0mg injection instead of two 40 mg injections at induction of their treatment.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'AMIFAMPRIDINE \\n\\nTablet 10 mg\\n\\nRuzurgi®\\n\\nThe Trustee For Orspec Pharma Unit Trust\\n\\nCategory 1 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Lambert-Eaton myasthenic syndrome', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a General Schedule Authority Required (Written) listing for the treatment of Lambert-Eaton myasthenic syndrome in adults and children aged six years and above.', 'PBAC OUTCOME\\n': 'The PBAC did not recommend the listing of amifampridine for the treatment of Lambert-Eaton myasthenic syndrome in adults and children aged 6 years and above. The PBAC noted the high clinical need for effective treatments for these patients. The PBAC considered that the submission’s claim of superior comparative effectiveness was reasonable, however the magnitude of the effect was uncertain due to the limitations of the available clinical evidence and the high risk of bias. The PBAC considered that amifampridine was inferior to placebo in terms of comparative safety. The PBAC considered the incremental cost effectiveness ratio was unacceptably high and uncertain at the proposed price. The PBAC nominated the Early Re-entry re-submission pathway for this item.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'AMIFAMPRIDINE \\n\\nTablet 10 mg\\n\\nRuzurgi®\\n\\nThe Trustee For Orspec Pharma Unit Trust\\n\\nCategory 1 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Lambert-Eaton myasthenic syndrome', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a General Schedule Authority Required (Written) listing for the treatment of Lambert-Eaton myasthenic syndrome in adults and children aged six years and above.', 'PBAC OUTCOME\\n': 'Sponsor’s comment: The sponsor had no comment.\\n'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'APALUTAMIDE \\n\\nTablet 60 mg\\n\\nErlyand®\\n\\nJanssen-Cilag Pty Ltd\\n\\nCategory 2 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Prostate cancer', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a General Schedule Authority Required listing for the treatment of patients with metastatic hormone-sensitive prostate cancer who have low-volume disease, or who have high-volume disease and are too frail for chemotherapy.', 'PBAC OUTCOME\\n': 'The PBAC did not recommend apalutamide for the treatment of metastatic hormone sensitive prostate cancer (mHSPC) in patients who have low volume (LV) disease, or high volume (HV) disease and who are unsuitable for chemotherapy. The PBAC noted that although apalutamide provides a moderate clinical benefit compared to androgen deprivation therapy alone for patients with mHSPC, it considered that there were issues with the listed contraindications and comorbidities for docetaxel unsuitability in the proposed restriction for the HV population and hence, the comparator proposed. The PBAC considered that the incremental cost effectiveness ratios presented in the submission were highly uncertain and likely underestimated. In addition, the PBAC considered that the financial impact estimates were high and likely overestimated.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'APALUTAMIDE \\n\\nTablet 60 mg\\n\\nErlyand®\\n\\nJanssen-Cilag Pty Ltd\\n\\nCategory 2 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Prostate cancer', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a General Schedule Authority Required listing for the treatment of patients with metastatic hormone-sensitive prostate cancer who have low-volume disease, or who have high-volume disease and are too frail for chemotherapy.', 'PBAC OUTCOME\\n': 'Sponsor’s comment: Janssen is disappointed that the PBAC did not recommend Erlyand and considers that the population requested for listing are the mHSPC patients with the highest clinical need for additional PBS therapies. Janssen does not agree with the PBAC’s comment that apalutamide provides moderate clinical benefit versus ADT. The TITAN trial demonstrates that apalutamide is associated with a statistically significant and clinically important 39% reduction in the risk of death versus ADT after adjustment for treatment switching.\\n\\nJanssen recognise the challenges in defining the restriction for the requested population. However, inclusion of docetaxel as a comparator creates significant cost-effectiveness challenges for new agents to gain PBS reimbursement. We will review the details of the outcome to understand implications and consider next steps.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'APALUTAMIDE \\n\\nTablet 60 mg\\n\\nErlyand®\\n\\nJanssen-Cilag Pty Ltd\\n\\nStandard Re-entry submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Prostate cancer', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'Resubmission to request a General Schedule Authority Required listing for the treatment of castration-resistant prostate cancer with no distant metastases on conventional imaging. ', 'PBAC OUTCOME\\n': 'The PBAC recommended the listing of apalutamide for the treatment of patients with non-metastatic castration resistant prostate cancer. The PBAC was satisfied that apalutamide provides, for some patients, a moderate overall survival benefit compared to standard of care and was non-inferior in terms of efficacy and safety compared to darolutamide. The PBAC’s recommendation for listing was based on, among other matters, its assessment that the cost-effectiveness of apalutamide would be acceptable if it were cost-minimised to darolutamide. The PBAC recommended potential flow on changes to the PBS restrictions for darolutamide, abiraterone and enzalutamide to prevent the subsequent use of novel hormonal agents.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'AVALGLUCOSIDASE ALFA\\n\\nPowder for injection 100 mg in 10 mL\\n\\nNexviazyme®\\n\\nSanofi-Aventis Australia Pty Ltd\\n\\nCategory 2 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Pompe disease', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a Section 100 (Highly Specialised Drugs Program) Authority Required listing for the treatment of Pompe disease. ', 'PBAC OUTCOME\\n': 'The PBAC did not recommend the Section 100 (Highly Specialised Drugs Program) listing of avalglucosidase alfa (AVAL) for the treatment of infantile-onset Pompe disease (IOPD), juvenile-onset Pompe disease (JOPD) or adult-onset Pompe disease (AOPD). The primary comparator for AVAL was alglucosidase alfa (ALGLU), a medicine currently included on the life-saving drugs program for this population.  The PBAC considered AVAL treatment for late onset Pompe disease (LOPD), including the AOPD and JOPD populations, was likely non-inferior to ALGLU. The PBAC considered the lack of evidence for the IOPD population made the clinical claim of non-inferiority for that population highly uncertain but that, overall, AVAL was likely to provide similar health outcomes to ALGLU. The PBAC considered AVAL was an effective treatment for IOPD and LOPD (compared to no treatment) but the extent of benefit was uncertain. The PBAC considered the incremental cost effectiveness ratio for AVAL compared to no treatment was very high and uncertain.  '}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'AVALGLUCOSIDASE ALFA\\n\\nPowder for injection 100 mg in 10 mL\\n\\nNexviazyme®\\n\\nSanofi-Aventis Australia Pty Ltd\\n\\nCategory 2 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Pompe disease', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a Section 100 (Highly Specialised Drugs Program) Authority Required listing for the treatment of Pompe disease. ', 'PBAC OUTCOME\\n': 'Sponsor’s comment: The sponsor had no comment.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'BEVACIZUMAB\\n\\nSolution for I.V. infusion 100 mg in 4 mL\\nSolution for I.V. infusion 400 mg in 16 mL\\n\\nAbevmy®\\n\\nAlphapharm Pty Ltd\\n\\nCategory 3 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Relapsed or recurrent glioblastoma;\\nAdvanced (unresectable) Barcelona Clinic Liver Cancer;\\nStage B or Stage C hepatocellular carcinoma;\\nStage IV (metastatic) non-small cell lung cancer (NSCLC);\\nAdvanced carcinoma of cervix;\\nAdvanced International Federation of Gynecology and Obstetrics (FIGO) Stage IIIB, IIIC or Stage IV epithelial ovarian, fallopian tube or primary peritoneal cancer;\\nMetastatic colorectal cancer.', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request listing of bevacizumab biosimilar under the same conditions as its reference biologic.', 'PBAC OUTCOME\\n': 'The PBAC recommended the listing under Section 100 (Efficient Funding of Chemotherapy), of a new biosimilar brand of bevacizumab, Abevmy, for the same conditions as the currently listed biosimilar brand, Mvasi®. The PBAC’s recommendation for listing was based on its assessment that the cost-effectiveness of Abevmy would be acceptable if it were cost-minimised to Mvasi. '}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'BUDESONIDE\\n\\nTablet (orally disintegrating) 0.5\\xa0mg\\n\\nTablet (orally disintegrating) 1\\xa0mg\\n\\nJorveza®\\n\\nDr Falk Pharma Australia Pty Ltd\\n\\nEarly Re-entry submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Eosinophilic oesophagitis (EoE)', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'Resubmission to request an Authority Required listing for the treatment of EoE.', 'PBAC OUTCOME\\n': 'The PBAC recommended the Authority Required (immediate assessment) listing of budesonide orally disintegrating tablets (BOT) for the treatment of EoE. The PBAC noted TGA approval for maintenance therapy of EoE and registration of BOT 0.5 mg for this indication. Although uncertainty remained regarding the cost-effectiveness, the PBAC considered BOT likely cost-effective at the proposed price. The PBAC considered the uptake used to inform the financial estimates and Risk Sharing Arrangement should be based on the March 2021 DUSC advice.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'BUPRENORPHINE\\n\\nBuvidal® Weekly:\\nInjection (modified release) 8\\xa0mg in 0.16 mL pre-filled syringe\\nInjection (modified release) 16\\xa0mg in 0.32 mL pre-filled syringe\\nInjection (modified release) 24\\xa0mg in 0.48 mL pre-filled syringe \\nInjection (modified release) 32\\xa0mg in 0.64 mL pre-filled syringe \\n\\nBuvidal® Monthly:\\nInjection (modified release) 64\\xa0mg in 0.18 mL pre-filled syringe\\nInjection (modified release) 96\\xa0mg in 0.27 mL pre-filled syringe\\nInjection (modified release) 128\\xa0mg in 0.36 mL pre-filled syringe\\nInjection (modified release) 160\\xa0mg in 0.45 mL pre-filled syringe (new strength)\\n\\nBuvidal® Weekly; Buvidal® Monthly\\n\\nCamurus Pty Ltd\\n\\nCategory 2 submission\\n(New PBS listing)\\n', 'DRUG TYPE AND USE\\n': 'Opioid dependence', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request: a General Schedule listing in addition to the existing Section 100 (Opiate Dependence Treatment Program) listing under the same circumstances as the currently listed Buvidal®; listing an additional 160 mg strength of Buvidal Monthly under the same circumstances as the currently listed Buvidal Monthly; removing the requirement that a patient must be stabilised on sublingual buprenorphine or buprenorphine/naloxone prior to commencing treatment with Buvidal to align with recent regulatory updates by the TGA.', 'PBAC OUTCOME\\n': 'The PBAC recommended the listing of the new form, 160 mg monthly prolonged release buprenorphine, for the treatment of opiate dependence on the basis that it should be available only under special arrangements under Section 100 for opiate dependence with restricted benefit. The PBAC also recommended changing the PBS restriction to remove the requirement for stabilisation on sublingual buprenorphine or sublingual buprenorphine/naloxone prior to commencing treatment with weekly prolonged release buprenorphine, consistent with the recent amendment to the TGA indication.\\n\\nThe PBAC did not recommend the requested price increase and could not make a decision for the consideration of the Section 85 (Restricted Benefit) listing in addition to the current Section 100 (Opiate Dependence Treatment Program). The PBAC noted the current Post-market Review of Opiate Dependence Treatment Program medicines (ODTP PMR), which will consider barriers to access including affordability of ODTP medicines. The PBAC considered that the request for dual Section 85/100 listing should be informed by the ODTP PMR. The sponsor may wish to resubmit to the PBAC concerning these matters after the outcomes of the ODTP PMR become available.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'CABOTEGRAVIR\\n\\nTablet containing cabotegravir 30 mg\\n\\nVocabria®\\n\\n\\nCABOTEGRAVIR AND\\nRILPIVIRINE\\n\\nPack containing 1 injection of cabotegravir 600 mg in 3 mL and 1 injection of rilpivirine 900 mg in 3 mL\\n\\nCabenuva®\\n\\nViiV Healthcare Pty Ltd\\n\\nStandard Re-entry submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Human Immunodeficiency virus (HIV)', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'Resubmission to request a Section 100 (Highly Specialised Drugs Program - Community Access) Authority Required (STREAMLINED) listing for the treatment of HIV infection in adults who are virologically suppressed.', 'PBAC OUTCOME\\n': 'The PBAC recommended the Section 100 (Highly Specialised Drugs Program – Community Access) listing of cabotegravir and rilpirivine long-acting injectable (CAB LA + RPV LA) for the management of HIV infection. \\n\\nIn making this recommendation, the PBAC considered CAB LA + RPV LA to be of non-inferior comparative effectiveness to daily oral anti-retroviral therapy (ART) in terms of virologic suppression and recognised that some people living with HIV (PLHIV) in certain populations, such as Aboriginal and/or Torres Strait Islander people, those living in rural or remote settings, and individuals with complex living or social circumstances, had issues adhering to a daily oral regimen and would potentially have improved QoL from a long-acting injectable option administered in a clinical setting. The Committee welcomed the input from consumers and clinicians, which highlighted the potential benefits the listing of a long-acting injectable option may have for some PLHIV.\\n\\nThe PBAC considered the magnitude of this benefit was difficult to quantify and differentiate from patient preference or convenience factors, which may also lead some patients to take up a long-acting injectable option. The PBAC considered that as CAB LA + RPV LA offers benefits in terms of quality of life and increased adherence for some PLHIV compared to daily oral ART, a premium over the least costly alternative daily oral ART option was reasonable.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'CEMIPLIMAB \\n\\nSolution for I.V. infusion 350 mg in 7 mL\\n\\nLibtayo®\\n\\nSanofi-Aventis Australia Pty Ltd\\n\\nCategory 2 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Non-small cell lung cancer (NSCLC)', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (STREAMLINED) listing for the treatment of patients with stage IV NSCLC expressing PD-L1 with a tumour proportion score ≥50%. ', 'PBAC OUTCOME\\n': 'The PBAC recommended the Section 100 (Efficient Funding of Chemotherapy) Authority Required (STREAMLINED) listing of cemiplimab for the treatment of previously untreated metastatic NSCLC, in patients with a programmed cell death ligand 1 (PD-L1) tumour proportion score (TPS) ≥50%. The PBAC’s recommendation for listing was based on, among other matters, its assessment that the cost-effectiveness of cemiplimab would be acceptable if it were cost-minimised against pembrolizumab. The PBAC advised that the equi-effective doses are cemiplimab 350 mg Q3W and pembrolizumab 200 mg Q3W. The PBAC advised flow on changes to the pembrolizumab NSCLC restriction criteria for consistency with the cemiplimab restriction criteria.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'CEMIPLIMAB \\n\\nSolution for I.V. infusion 350 mg in 7 mL\\n\\nLibtayo®\\n\\nSanofi-Aventis Australia Pty Ltd\\n\\nStandard Re-entry submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Squamous cell carcinoma (SCC)', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'Resubmission to request Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (STREAMLINED) listing for the treatment of metastatic or locally advanced cutaneous SCC in patients who are not candidates for curative surgery or curative radiation. ', 'PBAC OUTCOME\\n': 'To be considered at a future PBAC meeting'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'CLADRIBINE \\n\\nTablet 10 mg\\n\\nMavenclad®\\n\\nMerck Healthcare Pty Ltd\\n\\nCategory 2 submission\\n(Other business)', 'DRUG TYPE AND USE\\n': 'Multiple sclerosis', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request the PBAC consider the equi-effective doses of cladribine and other PBS-listed therapies for the treatment of relapsing-remitting multiple sclerosis.', 'PBAC OUTCOME\\n': 'The PBAC did not recommend amending the existing \\nequi-effective doses of cladribine and fingolimod (and other disease modifying therapies (DMTs)) for the treatment of relapsing-remitting multiple sclerosis (RRMS), on the basis that the evidence presented did not satisfactorily establish that 2 years of treatment with cladribine (plus 1 or 2 years of no treatment) is non-inferior to either 3 or 4 years of treatment with fingolimod.\\n\\nIn making the decision not to recommend re-specifying the \\nequi-effective doses, the PBAC considered the clinical comparison presented, primarily based on a naïve comparison of the extension phases of the CLARITY (cladribine) and FREEDOMS (fingolimod) studies was not reliable for decision-making due to a lack of comparability between the studies. \\n\\nFurther, the PBAC considered that the real-world evidence presented was not reliable for the purposes of establishing \\nnon-inferiority as it did not include direct measures of the comparative effectiveness of cladribine and fingolimod in years 3 and 4.\\n\\nThe PBAC considered that the existing equi-effective doses and therapeutic relativities for cladribine and fingolimod remained appropriate.\\n\\nSponsor’s comment: The sponsor had no comment.\\n'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'DAPAGLIFLOZIN \\n\\nTablet 10 mg \\n\\nForxiga® \\n\\nAstraZeneca Pty Ltd\\n\\nMatters Outstanding\\n(Change to PBS listing)', 'DRUG TYPE AND USE\\n': 'Chronic kidney disease', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To consider new information from the sponsor following deferral of both dapagliflozin submissions at the July 2021 PBAC meeting. ', 'PBAC OUTCOME\\n': 'The PBAC did not recommend extending the existing listing of dapagliflozin to include a General Schedule Authority Required (STREAMLINED) listing for the treatment of patients with chronic kidney disease. The PBAC reiterated that it was satisfied that dapagliflozin added to standard care provides, for some patients, a significant improvement in efficacy over standard care alone. \\nThe PBAC remained of the view that the listing would be cost-effective at the price proposed in the pre-PBAC response from July 2021. However, the revised financial estimates remained high and uncertain, and did not form a reliable basis for a Risk Sharing Arrangement with the Australian Government. The PBAC considered that the outstanding issues could be easily resolved in a simple resubmission for dapagliflozin using the early re-entry pathway.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'DAPAGLIFLOZIN \\n\\nTablet 10 mg \\n\\nForxiga® \\n\\nAstraZeneca Pty Ltd\\n\\nMatters Outstanding\\n(Change to PBS listing)', 'DRUG TYPE AND USE\\n': 'Chronic kidney disease', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To consider new information from the sponsor following deferral of both dapagliflozin submissions at the July 2021 PBAC meeting. ', 'PBAC OUTCOME\\n': 'Sponsor’s comment: The sponsor had no comment.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'DARATUMUMAB \\n\\nSolution for subcutaneous injection 1,800 mg in 15 mL vial\\n\\nDarzalex® SC\\n\\nJanssen-Cilag Pty Ltd\\n\\nCategory 1 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Amyloid light-chain (AL) amyloidosis', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a Section 100 (Highly Specialised Drugs Program) Authority Required listing, for use in combination with cyclophosphamide, bortezomib and dexamethasone, for the treatment of patients with newly diagnosed AL amyloidosis.', 'PBAC OUTCOME\\n': 'The PBAC did not recommend daratumumab SC, for use in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) for the treatment of patients with newly diagnosed systemic AL amyloidosis. The PBAC recognised that there are no treatments on the PBS available specifically for this condition, and it considered that the addition of daratumumab SC plus CyBorD offered high added therapeutic value. However, the PBAC considered that there were uncertainties in the cost-effectiveness analysis and financial estimates, particularly due to the overlap between patients with AL amyloidosis and multiple myeloma. The PBAC considered that these uncertainties could be managed through a re-specified economic analysis that included more conservative assumptions, and a Risk Sharing Arrangement.\\nThe PBAC nominated the Early Resolution re-submission pathway for this item.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'DARATUMUMAB \\n\\nSolution for subcutaneous injection 1,800 mg in 15 mL vial\\n\\nDarzalex® SC\\n\\nJanssen-Cilag Pty Ltd\\n\\nCategory 1 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Amyloid light-chain (AL) amyloidosis', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a Section 100 (Highly Specialised Drugs Program) Authority Required listing, for use in combination with cyclophosphamide, bortezomib and dexamethasone, for the treatment of patients with newly diagnosed AL amyloidosis.', 'PBAC OUTCOME\\n': 'Sponsor’s comment: Whilst Janssen is disappointed that the PBAC did not recommend daratumumab for systemic AL amyloidosis, we welcome the PBAC’s nomination of the early resolution pathway having recognised that daratumumab offered high added therapeutic value for a population with high and urgent unmet medical need for PBS reimbursed treatment. Janssen remains committed to ensuring people with AL amyloidosis can access the best available treatments and will review the details of the outcome and the PBAC’s requirements to move forward with the early resolution pathway.\\n'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'ECULIZUMAB \\n\\nSolution concentrate for I.V. infusion 300 mg in 30 mL\\n\\nSoliris®\\n\\nAlexion Pharmaceuticals Australasia Pty Ltd\\n\\nStandard Re-entry submission\\n(Change to PBS listing)', 'DRUG TYPE AND USE\\n': 'Neuromyelitis optica spectrum disorder (NMOSD)', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'Resubmission to request an Authority Required (Written) listing for the treatment of patients with relapsing NMOSD who are anti-aquaporin-4 (AQP4) antibody positive.', 'PBAC OUTCOME\\n': 'The PBAC did not recommend the listing of eculizumab for the treatment of patients with NMOSD who are AQP4 antibody positive.\\n\\nAlthough the PBAC considered that eculizumab was more effective than best supportive care in reducing relapses, the magnitude of this effect on disability progression and quality of life remained highly uncertain.\\n\\nThe PBAC noted that although the resubmission partly addressed some of the concerns with the economic model, the incremental cost effectiveness ratio (ICER) remained excessively high (> $1,055,000 per quality adjusted life year) and advised that a substantial price reduction would be required to achieve an acceptable ICER.\\n\\nThe PBAC noted that although the number of eligible patients had been reduced compared to the November 2020 submission, as eculizumab was proposed as a lifelong prophylactic treatment, at the proposed price, the cost of listing remained high.\\n\\nComparator: Best supportive care/placebo\\nThe PBAC accepted that best supportive care was an appropriate comparator but considered that rituximab is also a relevant compactor and a formal comparison would be informative.\\n\\nClinical claim: Superior effectiveness and non-inferior safety compared with best supportive care/placebo \\nThe PBAC considered that eculizumab was more effective than best supportive care/placebo in reducing relapses; however, the magnitude of this effect on disability progression and quality of life outcomes remained highly uncertain.\\n\\nThe PBAC considered that the claim of non-inferior comparative safety was reasonable.\\n\\nEconomic claim: Cost-utility analysis compared with best supportive care/placebo.\\nThe PBAC considered the ICER remained unacceptably high. The PBAC noted that the resubmission only partly addressed some of the issues raised in response to the original submission.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'ECULIZUMAB \\n\\nSolution concentrate for I.V. infusion 300 mg in 30 mL\\n\\nSoliris®\\n\\nAlexion Pharmaceuticals Australasia Pty Ltd\\n\\nStandard Re-entry submission\\n(Change to PBS listing)', 'DRUG TYPE AND USE\\n': 'Neuromyelitis optica spectrum disorder (NMOSD)', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'Resubmission to request an Authority Required (Written) listing for the treatment of patients with relapsing NMOSD who are anti-aquaporin-4 (AQP4) antibody positive.', 'PBAC OUTCOME\\n': 'Sponsor’s comment: There are no TGA approved therapies reimbursed for neuromyelitis optica spectrum disorder (NMOSD) in Australia and given the severity and rare nature of this disease, Alexion is committed to continue to work with the Government to reach an agreement that ensures equitable access for people living with this devastating disease.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'EMPAGLIFLOZIN \\n\\nTablet 10 mg\\n\\nJardiance®\\n\\nBoehringer Ingelheim Pty Ltd\\n\\nCategory 2 submission\\n(Change to PBS listing)', 'DRUG TYPE AND USE\\n': 'Chronic heart failure', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a General Schedule Authority Required (STREAMLINED) listing for the treatment of patients with chronic heart failure with reduced ejection fraction.', 'PBAC OUTCOME\\n': 'The PBAC recommended the listing of empagliflozin for the treatment of patients with chronic heart failure with reduced ejection fraction (HFrEF), New York Heart Association classification II-IV, left ventricular ejection fraction (LVEF) ≤40%, who are receiving standard care including a beta blocker, and an angiotensin-converting enzyme inhibitor (ACEi), or an angiotensin II receptor blocker (ARB), or an angiotensin receptor with neprilysin inhibitor (ARNi). Although the submission presented a modelled economic evaluation against standard of care, the PBAC’s recommendation for listing was based on its assessment that the cost-effectiveness of empagliflozin would be acceptable if it were cost-minimised against dapagliflozin, which was recommended for listing of this indication at the PBAC’s September 2021 Intracycle meeting. The PBAC considered that a claim of non-inferior comparative effectiveness was adequately supported by the clinical evidence and international clinical guidelines, and advised that empagliflozin for HFrEF should share the expenditure caps that the PBAC had recommended for a Risk-Sharing Arrangement for dapagliflozin. The PBAC considered that the equi-effective doses were empagliflozin 10 mg per day and dapagliflozin 10 mg per day. '}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'ESSENTIAL AMINO ACIDS FORMULA WITH VITAMINS AND MINERALS\\n\\nSachets containing oral powder 12.5 g, 30\\n\\nEAA Supplement™ \\n\\nVitaflo Australia Pty Limited\\n\\nCategory 4 submission \\n(Change to PBS listing) ', 'DRUG TYPE AND USE\\n': 'Gyrate atrophy of the choroid and retina;\\nUrea cycle disorders', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request EAA Supplement with new formulation and new pack size continue to be listed on the PBS; and to request a change of maximum quantity from four packs (200 sachets) to six packs (180 sachets). ', 'PBAC OUTCOME\\n': 'The PBAC recommended the listing of EAA Supplement with new formulation, pack size and maximum quantity to replace the current PBS listed EAA Supplement.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'ETANERCEPT\\n\\nInjections 50 mg in 1 mL single use pre-filled syringes, 4\\n\\nRymti®\\n\\nAlphapharm Pty Ltd\\n\\nCategory 3 submission\\n(New PBS listing) ', 'DRUG TYPE AND USE\\n': 'Rheumatoid arthritis; \\nPlaque psoriasis; \\nAnkylosing spondylitis; \\nPsoriatic arthritis; \\nJuvenile idiopathic arthritis; \\nPaediatric plaque psoriasis.', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request listing of etanercept biosimilar under the same conditions as its reference biologic, with exclusion of children and adolescents who weigh less than 62.5 kg.', 'PBAC OUTCOME\\n': 'The PBAC recommended the Authority Required listing of Rymti in the form of 50 mg in 1 mL pre-filled syringe as a biosimilar brand of Enbrel®. The PBAC’s recommendation for listing was based on, among other matters, its assessment that the cost-effectiveness of Rymti would be acceptable if it were cost-minimised to Enbrel. The PBAC advised that, the same form and strength of Brenzys®, Enbrel and Rymti should be treated as equivalent to each other for the purpose of substitution.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'FLUTICASONE FUROATE WITH UMECLIDINIUM AND VILANTEROL\\n\\nPowder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25\\xa0micrograms (as trifenatate) per dose, 30 doses\\n\\nTrelegy® Ellipta® 200/62.5/25\\n\\nGlaxoSmithKline Australia Pty Ltd\\n\\nCategory 2 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Severe asthma', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a General Schedule Authority Required (STREAMLINED) listing for the treatment of severe asthma.', 'PBAC OUTCOME\\n': 'The PBAC recommended the Authority Required (STREAMLINED) listing of fluticasone furoate (FF) with umeclidinium (UMEC) and vilanterol (VI) fixed dose combination (FDC) for maintenance therapy of severe asthma. The recommended listing is for one strength: FF/UMEC/VI 200/62.5/25 mcg.\\n\\nThe PBAC considered the claim of non-inferior effectiveness and safety to the FDC of mometasone furoate (MF) 136 mcg, with indacaterol (IND) 114 mcg and glycopyrronium (GLY) 46 mcg was reasonable. The PBAC considered for purposes of satisfying Section 101(3B) of the National Health Act 1953, any high dose inhaled corticosteroid (ICS) with long-acting beta2-agonist (LABA) + tiotropium (TIO) combination are relevant alternative therapies. \\n\\nThe PBAC’s recommendation was therefore, among other matters, based on its assessment that the cost of FF/UMEC/VI should be no greater than the lowest price combination of the PBS listed components of triple therapy that are available for asthma at comparable doses. \\n\\nFlow-on restriction changes to the MF/IND/GLY FDC and tiotropium severe asthma listings were also recommended to make it consistent with FF/UMEC/VI, which includes amendment to an Authority Required (STREAMLINED) listing (MF/IND/GLY only; tiotropium would remain a Restricted Benefit).'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'FOLLITROPIN ALFA\\n\\nInjection 300 I.U. in 0.5 mL multi-dose cartridge\\nInjection 450 I.U. in 0.75 mL multi-dose cartridge\\nInjection 900 I.U. in 1.5 mL multi-dose cartridge\\n\\nGonal-f® Pen\\n\\nMerck Healthcare Pty Ltd\\n\\nCategory 2 submission\\n(Other business)', 'DRUG TYPE AND USE\\n': 'Assisted reproductive technology', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request the PBAC consider the therapeutic relativities of Gonal-f Pen and biosimilar therapies.', 'PBAC OUTCOME\\n': 'The PBAC did not recommend an increase to the price of Gonal-f as it considered that the clinical claim of the superior comparative effectiveness of Gonal-f to all of the follitropin alfa biosimilars was not adequately supported by the data presented in the submission. The PBAC also reaffirmed its previous advice that Gonal-f and Ovaleap® should be treated as equivalent to each other for the purposes of substitution.\\n\\n'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'FOLLITROPIN ALFA\\n\\nInjection 300 I.U. in 0.5 mL multi-dose cartridge\\nInjection 450 I.U. in 0.75 mL multi-dose cartridge\\nInjection 900 I.U. in 1.5 mL multi-dose cartridge\\n\\nGonal-f® Pen\\n\\nMerck Healthcare Pty Ltd\\n\\nCategory 2 submission\\n(Other business)', 'DRUG TYPE AND USE\\n': 'Assisted reproductive technology', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request the PBAC consider the therapeutic relativities of Gonal-f Pen and biosimilar therapies.', 'PBAC OUTCOME\\n': 'Sponsor’s comment: The sponsor had no comment.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'GEMTUZUMAB OZOGAMICIN\\n\\nPowder for Injection 5 mg\\n\\nMylotarg®\\n\\nPfizer Australia Pty Ltd\\n\\nStandard Re-entry submission\\n(New PBS listing) ', 'DRUG TYPE AND USE\\n': 'Acute myeloid leukaemia (AML)', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'Resubmission to request a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required listing for use in combination with standard intensive chemotherapy, for patients with previously untreated de novo CD33-positive AML, except acute promyelocytic leukaemia, who do not have a unfavourable cytogenetic profile. ', 'PBAC OUTCOME\\n': 'The PBAC recommended the listing of gemtuzumab ozogamicin, in combination with standard intensive chemotherapy (an anthracycline and cytarabine), for the treatment of patients with previously untreated, de novo CD33-positve AML except acute promyelocytic leukaemia, who have favourable/intermediate/unknown cytogenetic risk (where the unknown risk is due to inconclusive test results). The PBAC recommended that gemtuzumab ozogamicin should be available only under special arrangements under Section 100 (Efficient Funding of Chemotherapy Program). The PBAC is satisfied that gemtuzumab ozogamicin provides, for some patients, a significant improvement in efficacy over standard of care.\\n\\nThe PBAC remained of the view that the exact magnitude of the overall survival benefit was difficult to determine, and that the economic model was complex and difficult to assess. Nonetheless, although the resubmission had not addressed all areas of uncertainty, the PBAC considered that the cost-effectiveness of the listing would be acceptable, in the context of a reduced price offered and a high clinical need in a smaller, more defined population of patients most likely to see benefit, than that which had been assumed by the resubmission.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'GILTERITINIB \\n\\nTablet 40 mg (as fumarate)\\n\\nXospata®\\n\\nAstellas Pharma Australia Pty Ltd\\n\\nCategory 2 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Acute myeloid leukaemia (AML)', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a General Schedule Authority Required listing for the treatment of relapsed or refractory FLT3 mutation-positive AML.', 'PBAC OUTCOME\\n': 'The PBAC did not recommend the listing of gilteritinib for the treatment of relapsed or refractory FLT3 mutation-positive AML. The PBAC considered that the clinical claim of superior effectiveness over salvage chemotherapy may be reasonable, but that long-term survival was uncertain based on the available evidence. The PBAC considered that revisions to the inputs for the economic model were required, including, among other matters, removing use as maintenance therapy post hematopoietic stem-cell transplantation (HSCT), reducing the time horizon, and adjusting the point at which patients can be considered cured. A price reduction would be required to achieve cost-effectiveness under this revised scenario, and a resubmission would need to make corresponding updates and other changes to the financial estimates. \\n\\nThe PBAC nominated the Early Re-entry re-submission pathway for this item.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'GILTERITINIB \\n\\nTablet 40 mg (as fumarate)\\n\\nXospata®\\n\\nAstellas Pharma Australia Pty Ltd\\n\\nCategory 2 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Acute myeloid leukaemia (AML)', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a General Schedule Authority Required listing for the treatment of relapsed or refractory FLT3 mutation-positive AML.', 'PBAC OUTCOME\\n': 'Sponsor’s comment: Astellas Pharma Australia welcomes the PBAC feedback and will work towards the early re-entry re-submission pathway to resolve the outstanding issues, so patients in Australia with refractory or relapsed FLT3 mutation AML can greatly benefit from gilteritinib being available through the PBS.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'IMATINIB\\n\\nTablet 600 mg\\n\\nImatab®\\n\\nJuno Pharmaceuticals Pty Ltd\\n\\nCommittee Secretariat submission\\n(New PBS listing) ', 'DRUG TYPE AND USE\\n': 'Chronic myeloid leukaemia (CML);\\nPhiladelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL);\\nMyelodysplastic or myeloproliferative disorder (MDS/MPD);\\nAggressive systemic mastocytosis (ASM) with eosinophilia;\\nChronic eosinophilic leukaemia (CEL) or Hypereosinophilic syndrome (HES);\\nDermatofibrosarcoma protuberans (DFSP);\\nGastrointestinal stromal tumour (GIST);\\nMalignant GIST.', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request listing of an additional strength under the same circumstances as the currently listed imatinib.', 'PBAC OUTCOME\\n': 'The PBAC recommended the listing of imatinib (Imatab) 600 mg tablets on a cost-minimisation basis to the existing PBS listed imatinib 100 mg and 400 mg tablets, and under the same circumstances as the restrictions that allow for a daily dose of 600 mg with the exception of not allowing prescribers to request an increase to the maximum quantity.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'INSULIN ASPART \\n\\nInjections (human analogue), cartridges, 100 units per mL, 3 mL, 5\\nInjections (human analogue), pre-filled pen, 100 units per mL, 3 mL, 5\\n\\nTruvelog®; Truvelog® Solostar\\n\\nSanofi-Aventis Australia Pty Ltd\\n\\nCategory 3 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Diabetes mellitus', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request listing of insulin aspart biosimilars under the same conditions as their reference brands.', 'PBAC OUTCOME\\n': 'The PBAC recommended the listing of a new biosimilar brand of insulin aspart in the form of 100 IU/mL cartridge (Truvelog) and 100 IU/mL pre-filled pen (Truvelog Solostar), under the same circumstances as the PBS-listed reference brands, NovoRapid Penfill and NovoRapid Flexpen. The PBAC’s recommendation for listing was based on, among other matters, its assessment that the cost-effectiveness of Truvelog and Truvelog Solostar would be acceptable if they were cost-minimised to NovoRapid Penfill and NovoRapid Flexpen respectively.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'IXEKIZUMAB \\n\\nInjection 80 mg in 1 mL single dose pre-filled pen\\n\\nTaltz®\\n\\nEli Lilly Australia Pty Ltd\\n\\nCategory 2 submission\\n(Change to PBS listing) ', 'DRUG TYPE AND USE\\n': 'Non radiographic axial spondyloarthritis \\n(nr-axSpA)', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a General Schedule Authority Required (Written) listing for the treatment of nr-axSpA, under the same circumstances as currently PBS listed biological disease-modifying antirheumatic agents for this indication.', 'PBAC OUTCOME\\n': 'The PBAC recommended the Authority Required listing of ixekizumab for the treatment of nr-axSpA. The PBAC’s recommendation for listing was based on, among other matters, its assessment that the cost-effectiveness of ixekizumab would be acceptable if it were cost-minimised to the least costly biologic disease-modifying anti-rheumatic drug (bDMARD) for this indication. The PBAC noted the flow-on restriction changes to other bDMARD listings for nr-axSpA to include ixekizumab in the administrative notes that lists eligible therapies for this indication.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'LAROTRECTINIB \\n\\nCapsule 25 mg\\nCapsule 100 mg\\nOral solution 20 mg per mL, 100 mL\\n\\nVitrakvi®\\n\\nBayer Australia Ltd\\n\\nStandard Re-entry submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Solid tumours harbouring neurotrophic receptor tyrosine kinase (NTRK) gene fusions ', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'Resubmission to request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing for the treatment of adult and paediatric patients with locally advanced or metastatic solid tumours harbouring NTRK gene fusions.', 'PBAC OUTCOME\\n': 'Paediatric NTRK fusion population and adult high frequency NTRK fusion population\\nThe PBAC deferred making its decision on whether to recommend the listing of larotrectinib for the treatment of patients with NTRK fusion tumours that are either unresectable locally advanced, metastatic, or locally advanced and would otherwise require disfiguring surgery or limb amputation to achieve a complete surgical resection. The PBAC was of a mind to recommend the listing for paediatric patients with NTRK fusion tumours and adult patients with high frequency NTRK fusion tumours on the basis that the ICER was acceptable at the proposed price, pending MSAC advice on the funding of the codependent NTRK testing.\\n\\nAdult with low frequency NTRK fusion population \\nThe PBAC did not recommend the listing of larotrectinib for the treatment of adult patients with low frequency NTRK fusion tumours that are either unresectable locally advanced, metastatic, or locally advanced and would otherwise require disfiguring surgery or limb amputation to achieve a complete surgical resection. The PBAC considered that the incremental cost-effectiveness ratio (ICER) for this population remained high and uncertain. Further, the PBAC considered there is less unmet clinical need within this patient population given there are effective alternative treatments available for adult low frequency NTRK fusion tumours.\\n\\nThe PBAC considered that an incremental benefit of larotrectinib compared to Standard of Care in the adult low frequency subgroup was not clearly supported by the additional larotrectinib single-arm data and noted that the data remained immature at the latest data cut.\\n\\nThe PBAC advised that, given there would unlikely be sufficient data forthcoming to address the uncertainty around the effectiveness of larotrectinib, a further substantial price reduction would be required to achieve a cost-effective price. \\n\\nComparator: Standard of Care (SoC)\\nThe PBAC considered that the comparators specified in the resubmission were more representative of current SoC in the last treatment line setting where larotrectinib is proposed to be used in the adult low frequency subgroup.\\n\\nClinical claim: Superior effectiveness and non-inferior safety compared with SoC\\nThe PBAC maintained its previous consideration that the claim of superior effectiveness compared to SoC for the low frequency adult population was not sufficiently supported. The PBAC maintained that, overall, the available data indicated a manageable safety profile for larotrectinib, although there were insufficient data to assess the long-term safety of larotrectinib.\\n\\n\\n\\n\\n\\n\\nEconomic claim: Cost-utility analysis compared with SoC\\nThe PBAC considered the ICER was uncertain and likely underestimated given there was insufficient evidence to support an incremental benefit compared to SoC. The PBAC noted that the analysis for the adult low frequency tumour subgroup was particularly sensitive to the time horizon, OS and PFS extrapolation and duration of lenvatinib SoC treatment duration.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'LAROTRECTINIB \\n\\nCapsule 25 mg\\nCapsule 100 mg\\nOral solution 20 mg per mL, 100 mL\\n\\nVitrakvi®\\n\\nBayer Australia Ltd\\n\\nStandard Re-entry submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Solid tumours harbouring neurotrophic receptor tyrosine kinase (NTRK) gene fusions ', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'Resubmission to request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing for the treatment of adult and paediatric patients with locally advanced or metastatic solid tumours harbouring NTRK gene fusions.', 'PBAC OUTCOME\\n': 'Sponsor’s comment: Bayer welcomes the PBAC’s minded recommendation for the paediatric patients with NTRK gene fusion tumours and adult patients with high frequency NTRK gene fusion tumours. Bayer will continue to work with the PBAC to enable earliest possible access to larotrectinib for these patients following MSAC’s outcome.\\n\\nBayer is disappointed the PBAC did not recommend larotrectinib for adult low frequency NTRK gene fusion population. Bayer maintains larotrectinib provides significant clinically relevant benefit for all patients with solid tumours harbouring a NTRK gene fusion. Bayer will continue to work with the PBAC and collaborate with all stakeholders to find a suitable path forward for the adult with low frequency NTRK gene fusion patient population.\\n'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'MECASERMIN \\n\\nSolution for injection 40 mg in 4\\xa0mL vial\\n\\nIncrelex®\\n\\nIpsen Pty Ltd\\n\\nCategory 1 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Primary insulin-like growth factor 1 deficiency (Primary IGFD)', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a Section 100 Authority Required (Written) listing for the treatment of children and adolescents with growth failure due to primary IGFD.', 'PBAC OUTCOME\\n': 'The PBAC did not recommend mecasermin for the long-term treatment of growth failure in children and adolescents from 2 to 18 years with severe Primary IGFD. The PBAC noted that no other therapies are currently available for this condition. The PBAC considered that a claim of superior efficacy was reasonable based on improved height outcomes, however mecasermin has inferior safety when compared with no treatment. The PBAC considered the proposed PBS criteria inadequately defined the appropriate patient population. The PBAC considered that the incremental cost effectiveness ratio was high and uncertain at the proposed price, and that further validation of the estimated utilisation was required. \\n\\nThe PBAC nominated the Early Re-entry re-submission pathway for this item.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'MECASERMIN \\n\\nSolution for injection 40 mg in 4\\xa0mL vial\\n\\nIncrelex®\\n\\nIpsen Pty Ltd\\n\\nCategory 1 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Primary insulin-like growth factor 1 deficiency (Primary IGFD)', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a Section 100 Authority Required (Written) listing for the treatment of children and adolescents with growth failure due to primary IGFD.', 'PBAC OUTCOME\\n': 'Sponsor’s comment: Ipsen thanks the PBAC for their recognition of the unmet need in patients with severe Primary IGFD, and looks forward to further working with the committee in order to reach an outcome for children with this rare condition.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'MEPOLIZUMAB \\n\\nInjection 100 mg in 1 mL single dose pre-filled pen\\n\\nNucala®\\n\\nGlaxoSmithKline Australia Pty Ltd\\n\\nCategory 1 submission\\n(Change to PBS listing)', 'DRUG TYPE AND USE\\n': 'Chronic rhinosinusitis with nasal polyps', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing for the treatment of chronic rhinosinusitis with nasal polyps.', 'PBAC OUTCOME\\n': 'The PBAC did not recommend mepolizumab for treatment of chronic rhinosinusitis (CRS) with nasal polyps (NP; collectively CRSwNP) for patients who have received at least one previous surgery for the removal of NP. Overall, the PBAC considered the clinical claim of superior effectiveness compared SoC was reasonable in patients with CRSwNP. However, the PBAC considered the blood eosinophil count (BEC) threshold for access to mepolizumab should be increased from ≥150 cells/µL to ≥300 cells/µL. The PBAC considered that the submission had underestimated the incremental cost-effectiveness ratio (ICER) due to reliance on optimistic assumptions and inputs in the economic model. The PBAC considered the revised base case proposed by ESC was appropriate and that the resulting revised ICER high and uncertain at the proposed price. The PBAC considered the financial estimates were highly uncertain and advised that a Risk Sharing Arrangement would be required if patients unsuitable for surgery were to be included.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'MEPOLIZUMAB \\n\\nInjection 100 mg in 1 mL single dose pre-filled pen\\n\\nNucala®\\n\\nGlaxoSmithKline Australia Pty Ltd\\n\\nCategory 1 submission\\n(Change to PBS listing)', 'DRUG TYPE AND USE\\n': 'Chronic rhinosinusitis with nasal polyps', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing for the treatment of chronic rhinosinusitis with nasal polyps.', 'PBAC OUTCOME\\n': 'Sponsor’s comment: GSK looks forward to working with the PBAC to ensure timely access to mepolizumab (Nucala) for people with chronic rhinosinusitis with nasal polyps (CRSwNP), a chronic condition with limited treatment options currently available in Australia. '}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'NIVOLUMAB \\n\\nInjection concentrate for I.V. infusion 40 mg in 4 mL\\nInjection concentrate for I.V. infusion 100 mg in 10 mL\\n\\nOpdivo®\\n\\nBristol-Myers Squibb Australia Pty Ltd\\n\\nCategory 2 submission\\n(Change to PBS listing)', 'DRUG TYPE AND USE\\n': 'Non-human epidermal growth factor receptor 2 (HER-2) positive gastric cancer, gastroesophageal junction cancer or oesophageal adenocarcinoma', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (STREAMLINED) listing for the first-line treatment of patients with advanced or metastatic non-HER-2-positive gastric cancer, gastroesophageal junction cancer or oesophageal adenocarcinoma.', 'PBAC OUTCOME\\n': 'The PBAC did not recommend the listing of nivolumab in combination with chemotherapy for the treatment of treatment of advanced or metastatic non-HER-2 positive advanced or metastatic gastric cancer, gastro-oesophageal junction cancer, or oesophageal adenocarcinoma. The PBAC noted that the clinical need for effective treatments in this therapeutic area is high, given the poor prognosis for patients and the poor efficacy and high toxicity of current treatments. The PBAC considered the evidence presented demonstrated treatment with nivolumab resulted in a clinically meaningful improvement in progression free survival and overall survival. However, the PBAC considered the incremental cost-effectiveness ratio in this setting at the proposed price was high and moderately uncertain. \\n\\nThe PBAC nominated the Early Resolution re-submission pathway for this item.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'NIVOLUMAB \\n\\nInjection concentrate for I.V. infusion 40 mg in 4 mL\\nInjection concentrate for I.V. infusion 100 mg in 10 mL\\n\\nOpdivo®\\n\\nBristol-Myers Squibb Australia Pty Ltd\\n\\nCategory 2 submission\\n(Change to PBS listing)', 'DRUG TYPE AND USE\\n': 'Non-human epidermal growth factor receptor 2 (HER-2) positive gastric cancer, gastroesophageal junction cancer or oesophageal adenocarcinoma', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (STREAMLINED) listing for the first-line treatment of patients with advanced or metastatic non-HER-2-positive gastric cancer, gastroesophageal junction cancer or oesophageal adenocarcinoma.', 'PBAC OUTCOME\\n': 'Sponsor’s comment: Bristol-Myers Squibb Australia looks forward to continuing to work with the PBAC and the Department of Health to provide access to nivolumab plus chemotherapy for the first-line treatment of patients with non-HER2-positive advanced or metastatic gastric cancer, gastroesophageal junction cancer or oesophageal adenocarcinoma.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'OLAPARIB \\n\\nTablet 100 mg\\nTablet 150 mg\\n\\nLynparza®\\n\\nAstraZeneca Pty Ltd\\n\\nStandard Re-entry \\n(Change to PBS listing)', 'DRUG TYPE AND USE\\n': 'Prostate cancer', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'Resubmission to request a General Schedule Authority Required listing for the treatment of adult patients with metastatic castration-resistant prostate cancer and homologous recombination repair BRCA1/2 gene variants (somatic and/or germline) who have progressed following a prior novel hormonal agent.', 'PBAC OUTCOME\\n': 'The PBAC recommended olaparib for the treatment of metastatic castration resistant prostate cancer in patients with BRCA1 and BRCA2 pathogenic gene variants. The PBAC was satisfied that olaparib provides, for some patients, a significant improvement in efficacy over standard care (SoC), based on the results of the PROfound study. The PBAC considered that the mixed comparator of best supportive care (BSC) and cabazitaxel sufficiently reflected SoC in current Australian clinical practice and the comparator arm from the PROfound study could reasonably be used as a proxy for SoC. The PBAC noted that the resubmission had addressed a number of its previous concerns with the economic model and considered that the incremental cost-effectiveness ratio was within a cost-effective range despite some remaining uncertainty regarding the extent of the overall survival gain and the BRCA testing component.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'OMALIZUMAB \\n\\nXolair®\\n\\nNovartis Pharmaceuticals Australia Pty Limited\\n\\nCategory 4 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Uncontrolled severe asthma;\\nSevere chronic spontaneous urticaria;\\nUncontrolled severe allergic asthma', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To combine the existing listings of 75 mg and 150 mg strengths to allow patients requiring 225mg and 375mg, respectively, to pay a single co-payment.', 'PBAC OUTCOME\\n': 'The PBAC did not recommend combining the existing listings of the 75 mg and 150 mg strengths of omalizumab (Xolair) pre-filled syringe (PFS) under the Section 100 (Highly Specialised Drugs Program). The PBAC noted that the consumer comments described the financial burden to some patients who are currently paying two monthly co-payments for the treatment of uncontrolled severe allergic asthma. The PBAC considered that a solution to allow affected patients to pay a single monthly co-payment instead of two monthly co-payments would be that: i) the sponsor seeks the ARTG registration of a co-pack or other form that provides for the required dose; and ii) seeks PBS listing of this product or products. The PBAC would welcome a submission for a co-pack of omalizumab 75 mg and 150 mg PFS.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'OMALIZUMAB \\n\\nXolair®\\n\\nNovartis Pharmaceuticals Australia Pty Limited\\n\\nCategory 4 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Uncontrolled severe asthma;\\nSevere chronic spontaneous urticaria;\\nUncontrolled severe allergic asthma', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To combine the existing listings of 75 mg and 150 mg strengths to allow patients requiring 225mg and 375mg, respectively, to pay a single co-payment.', 'PBAC OUTCOME\\n': 'Sponsor’s comment: Novartis is unable to supply a co-pack for Xolair PFS for reasons outlined in the submission, and is disappointed that the PBAC has not recommended the proposed alternative.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'PEMBROLIZUMAB \\n\\nSolution concentrate for I.V. infusion 100 mg in 4 mL\\n\\nKeytruda®\\n\\nMerck Sharp & Dohme (Australia) Pty Ltd\\n\\nStandard Re-entry submission\\n(Change to PBS listing)', 'DRUG TYPE AND USE\\n': 'Squamous cell carcinoma of the head and neck (SCCHN)', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'Resubmission to request a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (STREAMLINED) listing for the first-line treatment of recurrent or metastatic SCCHN.', 'PBAC OUTCOME\\n': 'The PBAC deferred its decision regarding pembrolizumab (Keytruda®) for first line treatment of recurrent or metastatic SCCHN in patients with programmed death ligand 1 (PD-L1) combined positive score (CPS) >1. The PBAC considered that, based on the data provided, pembrolizumab plus chemotherapy was clinically superior to first-line chemotherapy alone in the CPS ≥1 population and also in the allcomers population (regardless of CPS).\\n\\nThe PBAC considered that, based on the results of the Keynote 048 trial, it is not possible to determine whether patients with CPS <1 derive benefit from pembrolizumab + chemotherapy as the trial was not powered to show a difference between CPS ≥1 and CPS <1. A statistically significant survival benefit was observed in the allcomers population treated with pembrolizumab plus chemotherapy at the interim analysis and the final analysis. The PBAC advised that, on this basis, it was preferable that listing of pembrolizumab in combination with chemotherapy not exclude patients with CPS <1.\\n\\nThe PBAC considered that the claim of superior comparative effectiveness for pembrolizumab monotherapy was adequately supported by the data for patients with CPS ≥20. The PBAC was of a mind to recommend listing of pembrolizumab as the committee considered that the incremental cost-effectiveness ratios could be brought into an acceptable range with a price reduction, noting that the areas of uncertainty in the economic model had been somewhat reduced in the resubmission.\\n\\nThe PBAC noted that advice from the Medical Services Advisory Committee (MSAC) was required regarding the PD-L1 testing component of the codependent submission. Subject to this advice, the PBAC expressed a preference for recommending the CPS ≥20 threshold for pembrolizumab monotherapy and an allcomers population for pembrolizumab plus chemotherapy, noting that a greater price reduction would be required for the latter broader population compared to restricting to a CPS ≥1 threshold.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'PEMBROLIZUMAB \\n\\nSolution concentrate for I.V. infusion 100 mg in 4 mL\\n\\nKeytruda®\\n\\nMerck Sharp & Dohme (Australia) Pty Ltd\\n\\nStandard Re-entry submission\\n(Change to PBS listing)', 'DRUG TYPE AND USE\\n': 'Squamous cell carcinoma of the head and neck (SCCHN)', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'Resubmission to request a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (STREAMLINED) listing for the first-line treatment of recurrent or metastatic SCCHN.', 'PBAC OUTCOME\\n': 'Sponsor’s comment: MSD welcomes the opportunity to work with PBAC and MSAC to expedite availability of pembrolizumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'PEMBROLIZUMAB \\n\\nSolution concentrate for I.V. infusion 100 mg in 4 mL\\n\\nKeytruda®\\n\\nMerck Sharp & Dohme (Australia) Pty Ltd\\n\\nCategory 2 submission\\n(Change to PBS listing)', 'DRUG TYPE AND USE\\n': 'Oesophageal carcinoma or human epidermal growth factor receptor 2 (HER2)-negative gastroesophageal adenocarcinoma', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request listing a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (STREAMLINED) listing for the first-line treatment of locally advanced or metastatic oesophageal carcinoma or HER-2-negative gastroesophageal junction adenocarcinoma.', 'PBAC OUTCOME\\n': 'The PBAC did not recommend the listing of pembrolizumab, in combination with platinum-based chemotherapy, for the treatment of locally advanced (Stage III) or metastatic (Stage IV) oesophageal adenocarcinoma or oesophageal squamous cell carcinoma, or HER2-negative adenocarcinoma of the gastro-oesophageal junction. The PBAC noted the high clinical need for effective treatments in this therapeutic area. The PBAC considered the evidence presented demonstrated there was a clinically meaningful improvement in progression free survival and overall survival with pembrolizumab. However, the PBAC considered the incremental cost-effectiveness ratio in this setting at the proposed price was high and moderately uncertain.\\n\\nThe PBAC nominated the Early Resolution re-submission pathway for this item.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'PEMBROLIZUMAB \\n\\nSolution concentrate for I.V. infusion 100 mg in 4 mL\\n\\nKeytruda®\\n\\nMerck Sharp & Dohme (Australia) Pty Ltd\\n\\nCategory 2 submission\\n(Change to PBS listing)', 'DRUG TYPE AND USE\\n': 'Oesophageal carcinoma or human epidermal growth factor receptor 2 (HER2)-negative gastroesophageal adenocarcinoma', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request listing a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (STREAMLINED) listing for the first-line treatment of locally advanced or metastatic oesophageal carcinoma or HER-2-negative gastroesophageal junction adenocarcinoma.', 'PBAC OUTCOME\\n': 'Sponsor’s comment: MSD is pleased that the PBAC has recognised the high added therapeutic value that Keytruda® offers patients with oesophageal/GOJ cancer. MSD is looking forward to working with the PBAC to provide access to Keytruda® for this patient group as early as possible through the early resolution pathway.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE, 15 VALENT ADSORBED\\n\\n0.5 mL in pre-filled syringe\\n\\nTrade name to be confirmed\\n\\nMerck Sharp & Dohme (Australia) Pty Ltd\\n\\nCategory 2 submission\\n(New listing)', 'DRUG TYPE AND USE\\n': 'Prevention of pneumococcal disease', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request National Immunisation Program listing for the prevention of pneumococcal disease.', 'PBAC OUTCOME\\n': 'The PBAC recommended that a 15-valent pneumococcal conjugate vaccine be a designated vaccine for the purposes of the National Health Act 1953, for the prevention of pneumococcal disease in non-Indigenous adults aged ≥70 years, Indigenous adults aged ≥50 years, and individuals at increased risk of pneumococcal disease aged ≥18 years. The PBAC’s recommendation for listing was based on, among other matters, its assessment that the cost-effectiveness of the 15-valent pneumococcal conjugate vaccine would be acceptable if it were cost-minimised against the nominated comparator, Prevenar 13 (a 13-valent pneumococcal conjugate vaccine). '}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL\\n\\nEye drops 4mg-3mg per mL, single dose units 0.8 mL, 30\\n\\nSystane®\\n\\nAlcon Laboratories (Australia) Pty Ltd\\n\\nCategory 4 submission\\n(Change to PBS listing)', 'DRUG TYPE AND USE\\n': 'Severe dry eye syndrome', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a change in pack size from a pack of 28 x 0.8 mL unit doses to 30 x 0.8 mL unit doses.', 'PBAC OUTCOME\\n': 'The PBAC recommended listing a new pack size of Systane (polyethylene glycol 400 with propylene glycol) eye drops with 30 x 0.8 mL unit doses at the same price per unit as the currently listed 28 x 0.8 mL unit doses pack. '}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'PREGABALIN \\n\\nTablet 82.5 mg\\nTablet 165 mg\\nTablet 330 mg\\n\\nLyrica® CR\\n\\nUpjohn Australia Pty Ltd\\n\\nCategory 2 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Neuropathic pain', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a General Schedule Authority Required (STREAMLINED) listing for the treatment of neuropathic pain in adults, where this condition is refractory to treatment with other drugs.', 'PBAC OUTCOME\\n': 'The PBAC deferred making a recommendation for the listing of a controlled-released formulation of pregabalin (pregabalin CR) for the treatment of neuropathic pain to allow for utilisation analysis of immediate release pregabalin (pregabalin IR) and to further consider the potential quality use of medicines (QUM) issues with the CR formulation. \\n\\nThe PBAC expressed concern about reports of potential misuse and diversion of pregabalin (and gabapentinoids more broadly) in Australia. The Committee considered it was prudent to review the utilisation of pregabalin and to consider current evidence of misuse and diversion in Australia prior to forming a view as to whether additional forms of pregabalin should be recommended for listing on the PBS. Furthermore, the PBAC had additional QUM concerns specifically related to pregabalin CR which require further consideration, including the risk of prescribing errors, increased confusion amongst prescribers and patients and other factors unique to the controlled release formulation.\\n\\nThe PBAC referred the matter of pregabalin use to the Drug Utilisation Sub-Committee (DUSC) for consideration at a future meeting.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'PREGABALIN \\n\\nTablet 82.5 mg\\nTablet 165 mg\\nTablet 330 mg\\n\\nLyrica® CR\\n\\nUpjohn Australia Pty Ltd\\n\\nCategory 2 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Neuropathic pain', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a General Schedule Authority Required (STREAMLINED) listing for the treatment of neuropathic pain in adults, where this condition is refractory to treatment with other drugs.', 'PBAC OUTCOME\\n': 'Sponsor’s comment: The sponsor had no comment. '}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'PREGABALIN \\n\\nOral solution 20 mg per mL, 473 mL\\n\\nPregabalin-AFT®\\n\\nAFT Pharmaceuticals (Au) Pty Ltd\\n\\nCategory 4 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Neuropathic pain', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request an Authority Required (STREAMLINED) listing of pregabalin solution under the same circumstances as the existing listings of pregabalin capsules.', 'PBAC OUTCOME\\n': 'The PBAC deferred making a recommendation for the listing of pregabalin 20 mg per mL oral liquid (Pregabalin-AFT) for the treatment of neuropathic pain to allow for a review of the utilisation of the currently listed immediate release pregabalin capsules and to further consider potential quality use of medicines issues. \\n\\nThe PBAC expressed concern about reports of potential misuse and diversion of pregabalin (and gabapentinoids more broadly) in Australia. The Committee considered it was prudent to review the utilisation of pregabalin and to consider current evidence of misuse and diversion in Australia prior to forming a view as to whether additional forms of pregabalin should be recommended for listing on the PBS. \\n\\nThe PBAC referred the matter of pregabalin use to the Drug Utilisation Sub-Committee (DUSC) for consideration at a future meeting.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'PREGABALIN \\n\\nOral solution 20 mg per mL, 473 mL\\n\\nPregabalin-AFT®\\n\\nAFT Pharmaceuticals (Au) Pty Ltd\\n\\nCategory 4 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Neuropathic pain', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request an Authority Required (STREAMLINED) listing of pregabalin solution under the same circumstances as the existing listings of pregabalin capsules.', 'PBAC OUTCOME\\n': 'Sponsor’s comment: The sponsor had no comment. '}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'PROGESTERONE\\n\\nPessary 200 mg\\n\\nOripro®\\n\\nOrion Laboratories Pty Ltd\\n\\nCategory 4 submission\\n(Change to PBS listing)', 'DRUG TYPE AND USE\\n': 'Prevention of preterm birth', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request an increase of maximum quantity from 2 packs (30 units) to 3 packs (45 units), and a decrease in number of repeats from 5 to 3.', 'PBAC OUTCOME\\n': 'The PBAC recommended increasing the maximum quantity from 30 pessaries (2 packs) to 45 pessaries (3 packs) and reducing the number of repeats from 5 to 3 of the PBS listed progesterone 200 mg pessary (Oripro) for the prevention of preterm birth, to align the number of patient co-payments with another brand of progesterone (Utrogestan®).'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'REGORAFENIB \\n\\nTablet 40 mg (as monohydrate)\\n\\nStivarga®\\n\\nBayer Australia Ltd\\n\\nStandard Re-entry submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Colorectal cancer', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'Resubmission to request a General Schedule Authority Required (STREAMLINED) listing for beyond second-line treatment of patients with metastatic colorectal cancer.', 'PBAC OUTCOME\\n': 'The PBAC did not recommend the listing of regorafenib for the treatment of metastatic colorectal cancer (mCRC) after treatment with two or more prior therapies, on the basis that the evidence presented indicated regorafenib is toxic and would adversely impact patients’ overall quality of life, whilst having a limited impact on prognosis.\\n\\nThe PBAC considered while there was a clinical need for additional safe and effective later-line therapies in mCRC, the modest efficacy and poor safety profile of regorafenib meant it did not fulfil this need.\\n\\nComparator: Trifluridine/tipiracil\\nThe PBAC considered this was reasonable.\\n\\nClinical claim: Regorafenib is of non-inferior comparative effectiveness and safety to trifluridine/tipiracil\\nDespite uncertainties with the indirect comparisons and variability with the sensitivity analyses, the PBAC considered the claim of non-inferior comparative effectiveness to trifluridine/tipiracil was likely to be reasonable.\\n\\nThe PBAC noted the evidence presented indicated regorafenib is associated with significant risk of adverse events, including many of grade III or higher severity. The PBAC was particularly concerned about the high number of hand-foot skin reactions of this severity (16.6% in the CORRECT trial) and the impact on patients’ ability for self-care. It was also noted more than 7% of patients experienced diarrhoea at this level of severity, which may require hospitalisation. The PBAC also noted the TGA black box warning for rare cases of fatal hepatotoxicity. \\n\\nThe Committee considered regorafenib and trifluridine/tipiracil have distinct adverse event profiles, however it was noted the haematological adverse effects of trifluridine/tipiracil are generally easier to manage than the severe dermatological reactions with regorafenib, and regorafenib was associated with statistically significantly higher rates of adverse events leading to treatment discontinuation. Based on the available evidence, the PBAC did not agree with the submission’s claim of non-inferior comparative safety to trifluridine/tipiracil and considered reforafenib was likely inferior.\\n\\nEconomic claim: Cost minimisation approach versus trifluridine/tipiracil based on drug costs only.\\nThe PBAC considered the cost minimisation approach inappropriately did not include costs for differing adverse event management costs between regorafenib and trifluridine/tipiracil.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'REGORAFENIB \\n\\nTablet 40 mg (as monohydrate)\\n\\nStivarga®\\n\\nBayer Australia Ltd\\n\\nStandard Re-entry submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Colorectal cancer', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'Resubmission to request a General Schedule Authority Required (STREAMLINED) listing for beyond second-line treatment of patients with metastatic colorectal cancer.', 'PBAC OUTCOME\\n': 'Sponsor’s comment: Bayer is disappointed the PBAC did not recommend regorafenib for an additional later-line therapy for treatment of patients with mCRC.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'RISANKIZUMAB\\n\\nInjection 150mg in 1 mL pre-filled pen\\nInjection 150mg in 1 mL pre-filled syringe\\n\\nSkyrizi®\\n\\nAbbVie Pty Ltd\\n\\nCategory 4 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Severe chronic plaque psoriasis', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request listing of new forms of risankizumab under the same circumstances as the currently listed risankizumab.', 'PBAC OUTCOME\\n': 'The PBAC recommended the listing of risankizumab 150 mg/1 mL pre-filled pen (PFP) and 150 mg/1 mL PFS under the same circumstances as the currently listed risankizumab 75 mg/0.83 mL pre-filled syringe (PFS), on a cost-minimisation basis with the least costly biologic currently listed on the PBS for chronic plaque psoriasis. '}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'RITUXIMAB\\n\\nSolution for I.V. infusion 100 mg in 10 mL\\nSolution for I.V. infusion 500 mg in 50 mL\\n\\nRuxience®\\n\\nPfizer Australia Pty Ltd\\n\\nCategory 3 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Non-Hodgkin’s lymphoma (NHL); \\nChronic lymphocytic leukaemia (CLL);  \\nRheumatoid arthritis (RA); \\nGranulomatosis with polyangiitis (Wegener’s granulomatosis) (GPA);\\nMicroscopic polyangiitis (MPA) ', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request listing of rituximab biosimilar under the same conditions as the currently listed rituximab. ', 'PBAC OUTCOME\\n': 'The PBAC recommended the listing of a new biosimilar brand of rituximab (Ruxience) under the same conditions as the biosimilar brands currently listed on the PBS (Riximyo® and Truxima®). The PBAC’s recommendation for listing was based on its assessment that the cost-effectiveness of Ruxience would be acceptable if it were cost-minimised to Riximyo and Truxima.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'SACITUZUMAB GOVITECAN\\n\\nPowder for injection 180\\xa0mg\\n\\nTrodelvy®\\n\\nGilead Sciences Pty Limited\\n\\nCategory 1 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Breast cancer', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (STREAMLINED) listing for the treatment of adult patients with unresectable, locally advanced or metastatic triple negative breast cancer, who have received two or more prior therapies, at least one of them in the locally advanced or metastatic setting.', 'PBAC OUTCOME\\n': 'The PBAC did not recommend sacituzumab govitecan (SG) for the treatment of unresectable, locally advanced or metastatic triple negative breast cancer (TNBC). The PBAC considered that SG provides superior efficacy compared with the current standard of care, notably an improvement in overall survival and acknowledged the consumer comments that emphasised the impact of improved survival for this patient group. The PBAC also acknowledged the high clinical need for effective therapies for patients with this condition, who have poorer survival outcomes than patients with other breast cancer subtypes.\\n\\nHowever, the PBAC considered that specific inputs to the economic model should be revised and that the incremental cost-effectiveness ratio was unacceptably high at the proposed price. The PBAC considered that a price reduction would be required to achieve a cost-effective listing. \\n\\nThe PBAC nominated the Early Resolution re-submission pathway for this item.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'SACITUZUMAB GOVITECAN\\n\\nPowder for injection 180\\xa0mg\\n\\nTrodelvy®\\n\\nGilead Sciences Pty Limited\\n\\nCategory 1 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Breast cancer', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (STREAMLINED) listing for the treatment of adult patients with unresectable, locally advanced or metastatic triple negative breast cancer, who have received two or more prior therapies, at least one of them in the locally advanced or metastatic setting.', 'PBAC OUTCOME\\n': 'Sponsor’s comment: Gilead shares the PBAC’s view that sacituzumab govitecan addresses a high and urgent unmet clinical need in patients with unresectable, locally advanced or metastatic TNBC.\\n\\nThe company is working collaboratively with the PBAC and the Department under the early resolution re-submission pathway towards listing in the shortest possible time.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'SECUKINUMAB \\n\\nInjection 75 mg in 0.5 mL pre-filled syringe\\nInjection 150 mg in 1 mL pre-filled pen\\nInjection 300 mg in 2 mL pre-filled pen\\nInjection 300 mg in 2 mL pre-filled syringe\\n\\nCosentyx®\\n\\nNovartis Pharmaceuticals Australia Pty Limited\\n\\nCategory 2 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Paediatric psoriasis', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a General Schedule Authority Required (Written) listing for the treatment of paediatric patients with psoriasis, including the addition of a new 75 mg pre-filled syringe, 300 mg pre-filled pen and 300 mg pre-filled syringe.', 'PBAC OUTCOME\\n': 'The PBAC recommended the listing of secukinumab for the treatment of paediatric patients with severe chronic plaque psoriasis. Whilst there were limitations to the clinical comparison, the PBAC was satisfied that secukinumab is non-inferior to ustekinumab in this indication in the context of the available evidence. The PBAC considered that secukinumab would be cost-effective in paediatric patients at a price no greater than the price for ustekinumab in the same indication and population. \\n\\nThe PBAC noted flow on changes to the restriction criteria for ustekinumab and etanercept would be required.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'SILTUXIMAB\\n\\nPowder for injection 100 mg\\nPowder for injection 400 mg\\n\\nSylvant®\\n\\nEusa Pharma (UK) Ltd\\n\\nEarly Re-entry submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Idiopathic multicentric Castleman’s disease (iMCD)', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'Resubmission to request a Section 100 (Efficient Funding of Chemotherapy) Authority Required listing for the treatment of iMCD.', 'PBAC OUTCOME\\n': 'The PBAC recommended a Section 100 (Highly Specialised Drugs Program) listing of siltuximab for the treatment of iMCD. The PBAC considered that the revised economic model provided in the pre-PBAC response was reasonable and the resulting incremental cost-effectiveness ratio was within the acceptable range. The PBAC considered that its previous concerns about the financial estimates had been addressed with the prevalence-based approach provided in the resubmission. Overall, the PBAC considered that the concerns raised at the July 2021 meeting had been sufficiently addressed.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'TEPOTINIB \\n\\nTablet 225 mg (as hydrochloride monohydrate)\\n\\nTepmetko®\\n\\nMerck Healthcare Pty Ltd\\n\\nCategory 1 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Non-small cell lung cancer (NSCLC)', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a General Schedule Authority Required (STREAMLINED) listing for the treatment of patients with locally advanced or metastatic MET exon 14 skipping alterations-positive NSCLC.', 'PBAC OUTCOME\\n': 'The PBAC deferred making a recommendation to list tepotinib for the treatment of locally advanced or metastatic IV NSCLC patients who have evidence of a MET proto-oncogene, receptor tyrosine kinase (MET) gene alteration that causes skipping of exon 14 (METex14sk). The PBAC was of a mind to recommend tepotinib pending MSAC advice on the funding of the codependent METex14sk testing. The PBAC considered that, despite the uncertainties associated with the indirect comparisons presented in the submission, on balance, it was likely tepotinib provided similar health outcomes to pembrolizumab in combination with chemotherapy in the proposed population. The PBAC considered that tepotinib would be acceptably cost effective if it were cost-minimised against pembrolizumab in combination with chemotherapy, taking into account the number of patients needed to be tested to identify one patient with a METex14sk alteration. The PBAC considered a Risk Sharing Arrangement would be appropriate to manage the uncertainty associated with a number of cost-minimisation analysis inputs and assumptions, including the treatment duration of tepotinib.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'TEPOTINIB \\n\\nTablet 225 mg (as hydrochloride monohydrate)\\n\\nTepmetko®\\n\\nMerck Healthcare Pty Ltd\\n\\nCategory 1 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Non-small cell lung cancer (NSCLC)', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request a General Schedule Authority Required (STREAMLINED) listing for the treatment of patients with locally advanced or metastatic MET exon 14 skipping alterations-positive NSCLC.', 'PBAC OUTCOME\\n': 'Sponsor’s comment: The sponsor had no comment. '}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'TRASTUZUMAB\\n\\nPowder for I.V. infusion 440 mg\\n\\nHerzuma®\\n\\nCelltrion Healthcare Australia Pty Ltd\\n\\nCommittee Secretariat submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Metastatic (Stage IV) HER2 positive breast cancer;\\nMetastatic (Stage IV) HER2 positive \\nadenocarcinoma of the stomach or gastroesophageal junction;\\nEarly HER2 positive breast cancer', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To request listing of an additional strength under the same circumstances as the currently listed strengths of Herzuma.', 'PBAC OUTCOME\\n': 'The PBAC recommended the listing of a new vial size of 440 mg trastuzumab as Section 100 Efficient Funding of Chemotherapy program Authority Required (STREAMLINED) under the same conditions as the currently trastuzumab 60\\xa0mg, 150\\xa0mg and 420\\xa0mg listings'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'TRIENTINE \\n\\nTablet 150 mg (as tetrahydrochloride)\\n\\nCuprior®\\n\\nOrphalan\\n\\nCategory 1 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Wilson disease', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To seek a General Schedule Authority Required listing for the treatment of patients with Wilson disease who are intolerant to penicillamine.', 'PBAC OUTCOME\\n': 'The PBAC did not recommend trientine tetrahydrochloride (4HCl) for the treatment of patients with Wilson Disease (WD) intolerant to penicillamine/D-penicillamine (DPA) therapy. Although the PBAC accepted that chelation therapy prevents the progression of WD, the PBAC considered that the proposed place in therapy for trientine 4HCl and the nomination of best supportive care (BSC) as the comparator were unacceptable as they were inconsistent with current clinical practice and the available treatment guidelines. The PBAC therefore considered that the economic evaluation that compared trientine 4HCl with BSC was uninformative. In addition, the PBAC considered that the financial estimates were high, particularly at the proposed price. The PBAC considered that a cost-minimisation approach versus DPA would be more appropriate. \\n\\nThe PBAC nominated the Early Re-entry re-submission pathway for this item.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'TRIENTINE \\n\\nTablet 150 mg (as tetrahydrochloride)\\n\\nCuprior®\\n\\nOrphalan\\n\\nCategory 1 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Wilson disease', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To seek a General Schedule Authority Required listing for the treatment of patients with Wilson disease who are intolerant to penicillamine.', 'PBAC OUTCOME\\n': 'Sponsor’s comment: Orphalan is disappointed with the PBAC’s decision not to recommend a PBS listing for trientine 4HCl to treat WD. We are concerned that in this setting, there is now a lack of access to any effective chelating therapies to treat this life-threatening condition. We will continue to work with the PBAC process to help ensure equitable and sustainable access to trientine 4HCl for the patient population intolerant to DPA.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'TRIENTINE \\n\\nCapsule containing trientine dihydrochloride 250 mg (equivalent to 166.7 mg trientine)\\n\\nWaymade®\\n\\nClinect Pty Ltd\\n\\nCategory 1 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Wilson disease', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To seek a General Schedule Authority Required listing for the treatment of patients with Wilson disease who are intolerant to penicillamine.', 'PBAC OUTCOME\\n': 'The PBAC did not recommend trientine dihydrochloride (2HCl) for the treatment of patients with Wilson Disease (WD) intolerant to penicillamine/D-penicillamine (DPA) therapy. Although the PBAC accepted that chelation therapy prevents the progression of WD, the PBAC considered that the proposed place in therapy for trientine 2HCl and the nomination of no active treatment as the comparator were unacceptable as they were inconsistent with current clinical practice and the available treatment guidelines. The PBAC therefore considered that the economic evaluation that compared trientine 2HCl with no active treatment was uninformative. In addition, the PBAC considered that the financial estimates were high, particularly at the proposed price. The PBAC considered that a \\ncost-minimisation approach versus DPA would be more appropriate. \\n\\nThe PBAC nominated the Early Re-entry re-submission pathway for this item.'}, {'DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION': 'TRIENTINE \\n\\nCapsule containing trientine dihydrochloride 250 mg (equivalent to 166.7 mg trientine)\\n\\nWaymade®\\n\\nClinect Pty Ltd\\n\\nCategory 1 submission\\n(New PBS listing)', 'DRUG TYPE AND USE\\n': 'Wilson disease', 'LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION': 'To seek a General Schedule Authority Required listing for the treatment of patients with Wilson disease who are intolerant to penicillamine.', 'PBAC OUTCOME\\n': 'Sponsor’s comment: The sponsor had no comment. '}]\n"
     ]
    }
   ],
   "source": [
    "#Write a python function to extract table from pdf using python-docx\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "import docx\n",
    "import pandas as pd\n",
    "\n",
    "def extract_table(pdf_file):\n",
    "  # Create a Word document object\n",
    "  doc = docx.Document(pdf_file)\n",
    "  # Create an empty list to store the tables\n",
    "  tables = []\n",
    "  # Loop through the tables in the document\n",
    "  for table in doc.tables:\n",
    "    # Create an empty list to store the rows\n",
    "    rows = []\n",
    "    # Loop through the rows in the table\n",
    "    for row in table.rows:\n",
    "      # Create an empty list to store the cells\n",
    "      cells = []\n",
    "      # Loop through the cells in the row\n",
    "      for cell in row.cells:\n",
    "        # Add the text of the cell to the list\n",
    "        cells.append(cell.text)\n",
    "      # Add the list of cells to the list of rows\n",
    "      rows.append(cells)\n",
    "    # Add the list of rows to the list of tables\n",
    "    tables.append(rows)\n",
    "  # Return the list of tables as a pandas dataframe\n",
    "  return pd.DataFrame(tables[0][1:], columns=tables[0][0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "ename": "PackageNotFoundError",
     "evalue": "Package not found at './Download/pbac-web-outcomes-11-2021-v2.pdf'",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mPackageNotFoundError\u001b[0m                      Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[10], line 1\u001b[0m\n\u001b[1;32m----> 1\u001b[0m extract_table(\u001b[39m\"\u001b[39;49m\u001b[39m./Download/pbac-web-outcomes-11-2021-v2.pdf\u001b[39;49m\u001b[39m\"\u001b[39;49m)\n",
      "Cell \u001b[1;32mIn[9], line 6\u001b[0m, in \u001b[0;36mextract_table\u001b[1;34m(pdf_file)\u001b[0m\n\u001b[0;32m      4\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39mextract_table\u001b[39m(pdf_file):\n\u001b[0;32m      5\u001b[0m   \u001b[39m# Create a Word document object\u001b[39;00m\n\u001b[1;32m----> 6\u001b[0m   doc \u001b[39m=\u001b[39m docx\u001b[39m.\u001b[39;49mDocument(pdf_file)\n\u001b[0;32m      7\u001b[0m   \u001b[39m# Create an empty list to store the tables\u001b[39;00m\n\u001b[0;32m      8\u001b[0m   tables \u001b[39m=\u001b[39m []\n",
      "File \u001b[1;32mc:\\Users\\Himanshu\\anaconda3\\lib\\site-packages\\docx\\api.py:25\u001b[0m, in \u001b[0;36mDocument\u001b[1;34m(docx)\u001b[0m\n\u001b[0;32m     18\u001b[0m \u001b[39m\"\"\"\u001b[39;00m\n\u001b[0;32m     19\u001b[0m \u001b[39mReturn a |Document| object loaded from *docx*, where *docx* can be\u001b[39;00m\n\u001b[0;32m     20\u001b[0m \u001b[39meither a path to a ``.docx`` file (a string) or a file-like object. If\u001b[39;00m\n\u001b[0;32m     21\u001b[0m \u001b[39m*docx* is missing or ``None``, the built-in default document \"template\"\u001b[39;00m\n\u001b[0;32m     22\u001b[0m \u001b[39mis loaded.\u001b[39;00m\n\u001b[0;32m     23\u001b[0m \u001b[39m\"\"\"\u001b[39;00m\n\u001b[0;32m     24\u001b[0m docx \u001b[39m=\u001b[39m _default_docx_path() \u001b[39mif\u001b[39;00m docx \u001b[39mis\u001b[39;00m \u001b[39mNone\u001b[39;00m \u001b[39melse\u001b[39;00m docx\n\u001b[1;32m---> 25\u001b[0m document_part \u001b[39m=\u001b[39m Package\u001b[39m.\u001b[39;49mopen(docx)\u001b[39m.\u001b[39mmain_document_part\n\u001b[0;32m     26\u001b[0m \u001b[39mif\u001b[39;00m document_part\u001b[39m.\u001b[39mcontent_type \u001b[39m!=\u001b[39m CT\u001b[39m.\u001b[39mWML_DOCUMENT_MAIN:\n\u001b[0;32m     27\u001b[0m     tmpl \u001b[39m=\u001b[39m \u001b[39m\"\u001b[39m\u001b[39mfile \u001b[39m\u001b[39m'\u001b[39m\u001b[39m%s\u001b[39;00m\u001b[39m'\u001b[39m\u001b[39m is not a Word file, content type is \u001b[39m\u001b[39m'\u001b[39m\u001b[39m%s\u001b[39;00m\u001b[39m'\u001b[39m\u001b[39m\"\u001b[39m\n",
      "File \u001b[1;32mc:\\Users\\Himanshu\\anaconda3\\lib\\site-packages\\docx\\opc\\package.py:128\u001b[0m, in \u001b[0;36mOpcPackage.open\u001b[1;34m(cls, pkg_file)\u001b[0m\n\u001b[0;32m    122\u001b[0m \u001b[39m@classmethod\u001b[39m\n\u001b[0;32m    123\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39mopen\u001b[39m(\u001b[39mcls\u001b[39m, pkg_file):\n\u001b[0;32m    124\u001b[0m     \u001b[39m\"\"\"\u001b[39;00m\n\u001b[0;32m    125\u001b[0m \u001b[39m    Return an |OpcPackage| instance loaded with the contents of\u001b[39;00m\n\u001b[0;32m    126\u001b[0m \u001b[39m    *pkg_file*.\u001b[39;00m\n\u001b[0;32m    127\u001b[0m \u001b[39m    \"\"\"\u001b[39;00m\n\u001b[1;32m--> 128\u001b[0m     pkg_reader \u001b[39m=\u001b[39m PackageReader\u001b[39m.\u001b[39;49mfrom_file(pkg_file)\n\u001b[0;32m    129\u001b[0m     package \u001b[39m=\u001b[39m \u001b[39mcls\u001b[39m()\n\u001b[0;32m    130\u001b[0m     Unmarshaller\u001b[39m.\u001b[39munmarshal(pkg_reader, package, PartFactory)\n",
      "File \u001b[1;32mc:\\Users\\Himanshu\\anaconda3\\lib\\site-packages\\docx\\opc\\pkgreader.py:32\u001b[0m, in \u001b[0;36mPackageReader.from_file\u001b[1;34m(pkg_file)\u001b[0m\n\u001b[0;32m     27\u001b[0m \u001b[39m@staticmethod\u001b[39m\n\u001b[0;32m     28\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39mfrom_file\u001b[39m(pkg_file):\n\u001b[0;32m     29\u001b[0m     \u001b[39m\"\"\"\u001b[39;00m\n\u001b[0;32m     30\u001b[0m \u001b[39m    Return a |PackageReader| instance loaded with contents of *pkg_file*.\u001b[39;00m\n\u001b[0;32m     31\u001b[0m \u001b[39m    \"\"\"\u001b[39;00m\n\u001b[1;32m---> 32\u001b[0m     phys_reader \u001b[39m=\u001b[39m PhysPkgReader(pkg_file)\n\u001b[0;32m     33\u001b[0m     content_types \u001b[39m=\u001b[39m _ContentTypeMap\u001b[39m.\u001b[39mfrom_xml(phys_reader\u001b[39m.\u001b[39mcontent_types_xml)\n\u001b[0;32m     34\u001b[0m     pkg_srels \u001b[39m=\u001b[39m PackageReader\u001b[39m.\u001b[39m_srels_for(phys_reader, PACKAGE_URI)\n",
      "File \u001b[1;32mc:\\Users\\Himanshu\\anaconda3\\lib\\site-packages\\docx\\opc\\phys_pkg.py:30\u001b[0m, in \u001b[0;36mPhysPkgReader.__new__\u001b[1;34m(cls, pkg_file)\u001b[0m\n\u001b[0;32m     28\u001b[0m         reader_cls \u001b[39m=\u001b[39m _ZipPkgReader\n\u001b[0;32m     29\u001b[0m     \u001b[39melse\u001b[39;00m:\n\u001b[1;32m---> 30\u001b[0m         \u001b[39mraise\u001b[39;00m PackageNotFoundError(\n\u001b[0;32m     31\u001b[0m             \u001b[39m\"\u001b[39m\u001b[39mPackage not found at \u001b[39m\u001b[39m'\u001b[39m\u001b[39m%s\u001b[39;00m\u001b[39m'\u001b[39m\u001b[39m\"\u001b[39m \u001b[39m%\u001b[39m pkg_file\n\u001b[0;32m     32\u001b[0m         )\n\u001b[0;32m     33\u001b[0m \u001b[39melse\u001b[39;00m:  \u001b[39m# assume it's a stream and pass it to Zip reader to sort out\u001b[39;00m\n\u001b[0;32m     34\u001b[0m     reader_cls \u001b[39m=\u001b[39m _ZipPkgReader\n",
      "\u001b[1;31mPackageNotFoundError\u001b[0m: Package not found at './Download/pbac-web-outcomes-11-2021-v2.pdf'"
     ]
    }
   ],
   "source": [
    "extract_table(\"./Download/pbac-web-outcomes-11-2021-v2.pdf\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "ename": "PackageNotFoundError",
     "evalue": "Package not found at './Download/2021-11-05-PBAC-Web-Outcomes.docx'",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mPackageNotFoundError\u001b[0m                      Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[1], line 18\u001b[0m\n\u001b[0;32m     15\u001b[0m     \u001b[39mreturn\u001b[39;00m extracted_tables\n\u001b[0;32m     17\u001b[0m docx_path \u001b[39m=\u001b[39m \u001b[39m'\u001b[39m\u001b[39m./Download/2021-11-05-PBAC-Web-Outcomes.docx\u001b[39m\u001b[39m'\u001b[39m\n\u001b[1;32m---> 18\u001b[0m tables \u001b[39m=\u001b[39m extract_tables_from_docx(docx_path)\n\u001b[0;32m     19\u001b[0m \u001b[39mprint\u001b[39m(tables)\n",
      "Cell \u001b[1;32mIn[1], line 5\u001b[0m, in \u001b[0;36mextract_tables_from_docx\u001b[1;34m(docx_path)\u001b[0m\n\u001b[0;32m      4\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39mextract_tables_from_docx\u001b[39m(docx_path):\n\u001b[1;32m----> 5\u001b[0m     doc \u001b[39m=\u001b[39m Document(docx_path)\n\u001b[0;32m      6\u001b[0m     extracted_tables \u001b[39m=\u001b[39m []\n\u001b[0;32m      8\u001b[0m     \u001b[39mfor\u001b[39;00m table \u001b[39min\u001b[39;00m doc\u001b[39m.\u001b[39mtables:\n",
      "File \u001b[1;32mc:\\Users\\Himanshu\\anaconda3\\lib\\site-packages\\docx\\api.py:25\u001b[0m, in \u001b[0;36mDocument\u001b[1;34m(docx)\u001b[0m\n\u001b[0;32m     18\u001b[0m \u001b[39m\"\"\"\u001b[39;00m\n\u001b[0;32m     19\u001b[0m \u001b[39mReturn a |Document| object loaded from *docx*, where *docx* can be\u001b[39;00m\n\u001b[0;32m     20\u001b[0m \u001b[39meither a path to a ``.docx`` file (a string) or a file-like object. If\u001b[39;00m\n\u001b[0;32m     21\u001b[0m \u001b[39m*docx* is missing or ``None``, the built-in default document \"template\"\u001b[39;00m\n\u001b[0;32m     22\u001b[0m \u001b[39mis loaded.\u001b[39;00m\n\u001b[0;32m     23\u001b[0m \u001b[39m\"\"\"\u001b[39;00m\n\u001b[0;32m     24\u001b[0m docx \u001b[39m=\u001b[39m _default_docx_path() \u001b[39mif\u001b[39;00m docx \u001b[39mis\u001b[39;00m \u001b[39mNone\u001b[39;00m \u001b[39melse\u001b[39;00m docx\n\u001b[1;32m---> 25\u001b[0m document_part \u001b[39m=\u001b[39m Package\u001b[39m.\u001b[39;49mopen(docx)\u001b[39m.\u001b[39mmain_document_part\n\u001b[0;32m     26\u001b[0m \u001b[39mif\u001b[39;00m document_part\u001b[39m.\u001b[39mcontent_type \u001b[39m!=\u001b[39m CT\u001b[39m.\u001b[39mWML_DOCUMENT_MAIN:\n\u001b[0;32m     27\u001b[0m     tmpl \u001b[39m=\u001b[39m \u001b[39m\"\u001b[39m\u001b[39mfile \u001b[39m\u001b[39m'\u001b[39m\u001b[39m%s\u001b[39;00m\u001b[39m'\u001b[39m\u001b[39m is not a Word file, content type is \u001b[39m\u001b[39m'\u001b[39m\u001b[39m%s\u001b[39;00m\u001b[39m'\u001b[39m\u001b[39m\"\u001b[39m\n",
      "File \u001b[1;32mc:\\Users\\Himanshu\\anaconda3\\lib\\site-packages\\docx\\opc\\package.py:128\u001b[0m, in \u001b[0;36mOpcPackage.open\u001b[1;34m(cls, pkg_file)\u001b[0m\n\u001b[0;32m    122\u001b[0m \u001b[39m@classmethod\u001b[39m\n\u001b[0;32m    123\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39mopen\u001b[39m(\u001b[39mcls\u001b[39m, pkg_file):\n\u001b[0;32m    124\u001b[0m     \u001b[39m\"\"\"\u001b[39;00m\n\u001b[0;32m    125\u001b[0m \u001b[39m    Return an |OpcPackage| instance loaded with the contents of\u001b[39;00m\n\u001b[0;32m    126\u001b[0m \u001b[39m    *pkg_file*.\u001b[39;00m\n\u001b[0;32m    127\u001b[0m \u001b[39m    \"\"\"\u001b[39;00m\n\u001b[1;32m--> 128\u001b[0m     pkg_reader \u001b[39m=\u001b[39m PackageReader\u001b[39m.\u001b[39;49mfrom_file(pkg_file)\n\u001b[0;32m    129\u001b[0m     package \u001b[39m=\u001b[39m \u001b[39mcls\u001b[39m()\n\u001b[0;32m    130\u001b[0m     Unmarshaller\u001b[39m.\u001b[39munmarshal(pkg_reader, package, PartFactory)\n",
      "File \u001b[1;32mc:\\Users\\Himanshu\\anaconda3\\lib\\site-packages\\docx\\opc\\pkgreader.py:32\u001b[0m, in \u001b[0;36mPackageReader.from_file\u001b[1;34m(pkg_file)\u001b[0m\n\u001b[0;32m     27\u001b[0m \u001b[39m@staticmethod\u001b[39m\n\u001b[0;32m     28\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39mfrom_file\u001b[39m(pkg_file):\n\u001b[0;32m     29\u001b[0m     \u001b[39m\"\"\"\u001b[39;00m\n\u001b[0;32m     30\u001b[0m \u001b[39m    Return a |PackageReader| instance loaded with contents of *pkg_file*.\u001b[39;00m\n\u001b[0;32m     31\u001b[0m \u001b[39m    \"\"\"\u001b[39;00m\n\u001b[1;32m---> 32\u001b[0m     phys_reader \u001b[39m=\u001b[39m PhysPkgReader(pkg_file)\n\u001b[0;32m     33\u001b[0m     content_types \u001b[39m=\u001b[39m _ContentTypeMap\u001b[39m.\u001b[39mfrom_xml(phys_reader\u001b[39m.\u001b[39mcontent_types_xml)\n\u001b[0;32m     34\u001b[0m     pkg_srels \u001b[39m=\u001b[39m PackageReader\u001b[39m.\u001b[39m_srels_for(phys_reader, PACKAGE_URI)\n",
      "File \u001b[1;32mc:\\Users\\Himanshu\\anaconda3\\lib\\site-packages\\docx\\opc\\phys_pkg.py:30\u001b[0m, in \u001b[0;36mPhysPkgReader.__new__\u001b[1;34m(cls, pkg_file)\u001b[0m\n\u001b[0;32m     28\u001b[0m         reader_cls \u001b[39m=\u001b[39m _ZipPkgReader\n\u001b[0;32m     29\u001b[0m     \u001b[39melse\u001b[39;00m:\n\u001b[1;32m---> 30\u001b[0m         \u001b[39mraise\u001b[39;00m PackageNotFoundError(\n\u001b[0;32m     31\u001b[0m             \u001b[39m\"\u001b[39m\u001b[39mPackage not found at \u001b[39m\u001b[39m'\u001b[39m\u001b[39m%s\u001b[39;00m\u001b[39m'\u001b[39m\u001b[39m\"\u001b[39m \u001b[39m%\u001b[39m pkg_file\n\u001b[0;32m     32\u001b[0m         )\n\u001b[0;32m     33\u001b[0m \u001b[39melse\u001b[39;00m:  \u001b[39m# assume it's a stream and pass it to Zip reader to sort out\u001b[39;00m\n\u001b[0;32m     34\u001b[0m     reader_cls \u001b[39m=\u001b[39m _ZipPkgReader\n",
      "\u001b[1;31mPackageNotFoundError\u001b[0m: Package not found at './Download/2021-11-05-PBAC-Web-Outcomes.docx'"
     ]
    }
   ],
   "source": [
    "from docx import Document\n",
    "\n",
    "\n",
    "def extract_tables_from_docx(docx_path):\n",
    "    doc = Document(docx_path)\n",
    "    extracted_tables = []\n",
    "\n",
    "    for table in doc.tables:\n",
    "        extracted_table = []\n",
    "        for row in table.rows:\n",
    "            extracted_row = [cell.text for cell in row.cells]\n",
    "            extracted_table.append(extracted_row)\n",
    "        extracted_tables.append(extracted_table)\n",
    "\n",
    "    return extracted_tables\n",
    "\n",
    "docx_path = './Download/2021-11-05-PBAC-Web-Outcomes.docx'\n",
    "tables = extract_tables_from_docx(docx_path)\n",
    "print(tables)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "import docx\n",
    "def read_table_from_word_doc(doc_path): \n",
    "    doc = docx.Document(doc_path)\n",
    "    tables = doc.tables\n",
    "    tbl_list = []\n",
    "    for table in tables:\n",
    "        if len(table.columns) < 4:\n",
    "            continue\n",
    "        data = []\n",
    "        keys = None\n",
    "        for i, row in enumerate(table.rows):\n",
    "            text = (cell.text for cell in row.cells)\n",
    "            if i == 0:\n",
    "                keys = tuple(text)\n",
    "                continue\n",
    "            row_data = dict(zip(keys, text))\n",
    "            data.append(row_data)\n",
    "    tbl_list.append(pd.DataFrame(data))\n",
    "    return pd.concat(tbl_list).reset_index(drop=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "ename": "PackageNotFoundError",
     "evalue": "Package not found at 'e:\\Usecases\\Webscrape\\Download\\2021-11-05-PBAC-Web-Outcomes.docx'",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mPackageNotFoundError\u001b[0m                      Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[12], line 3\u001b[0m\n\u001b[0;32m      1\u001b[0m \u001b[39mimport\u001b[39;00m \u001b[39mos\u001b[39;00m\n\u001b[0;32m      2\u001b[0m doc_path \u001b[39m=\u001b[39m os\u001b[39m.\u001b[39mpath\u001b[39m.\u001b[39mabspath(\u001b[39m'\u001b[39m\u001b[39m./Download/2021-11-05-PBAC-Web-Outcomes.docx\u001b[39m\u001b[39m'\u001b[39m)\n\u001b[1;32m----> 3\u001b[0m read_table_from_word_doc(doc_path)\n",
      "Cell \u001b[1;32mIn[11], line 3\u001b[0m, in \u001b[0;36mread_table_from_word_doc\u001b[1;34m(doc_path)\u001b[0m\n\u001b[0;32m      2\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39mread_table_from_word_doc\u001b[39m(doc_path): \n\u001b[1;32m----> 3\u001b[0m     doc \u001b[39m=\u001b[39m docx\u001b[39m.\u001b[39;49mDocument(doc_path)\n\u001b[0;32m      4\u001b[0m     tables \u001b[39m=\u001b[39m doc\u001b[39m.\u001b[39mtables\n\u001b[0;32m      5\u001b[0m     tbl_list \u001b[39m=\u001b[39m []\n",
      "File \u001b[1;32mc:\\Users\\Himanshu\\anaconda3\\lib\\site-packages\\docx\\api.py:25\u001b[0m, in \u001b[0;36mDocument\u001b[1;34m(docx)\u001b[0m\n\u001b[0;32m     18\u001b[0m \u001b[39m\"\"\"\u001b[39;00m\n\u001b[0;32m     19\u001b[0m \u001b[39mReturn a |Document| object loaded from *docx*, where *docx* can be\u001b[39;00m\n\u001b[0;32m     20\u001b[0m \u001b[39meither a path to a ``.docx`` file (a string) or a file-like object. If\u001b[39;00m\n\u001b[0;32m     21\u001b[0m \u001b[39m*docx* is missing or ``None``, the built-in default document \"template\"\u001b[39;00m\n\u001b[0;32m     22\u001b[0m \u001b[39mis loaded.\u001b[39;00m\n\u001b[0;32m     23\u001b[0m \u001b[39m\"\"\"\u001b[39;00m\n\u001b[0;32m     24\u001b[0m docx \u001b[39m=\u001b[39m _default_docx_path() \u001b[39mif\u001b[39;00m docx \u001b[39mis\u001b[39;00m \u001b[39mNone\u001b[39;00m \u001b[39melse\u001b[39;00m docx\n\u001b[1;32m---> 25\u001b[0m document_part \u001b[39m=\u001b[39m Package\u001b[39m.\u001b[39;49mopen(docx)\u001b[39m.\u001b[39mmain_document_part\n\u001b[0;32m     26\u001b[0m \u001b[39mif\u001b[39;00m document_part\u001b[39m.\u001b[39mcontent_type \u001b[39m!=\u001b[39m CT\u001b[39m.\u001b[39mWML_DOCUMENT_MAIN:\n\u001b[0;32m     27\u001b[0m     tmpl \u001b[39m=\u001b[39m \u001b[39m\"\u001b[39m\u001b[39mfile \u001b[39m\u001b[39m'\u001b[39m\u001b[39m%s\u001b[39;00m\u001b[39m'\u001b[39m\u001b[39m is not a Word file, content type is \u001b[39m\u001b[39m'\u001b[39m\u001b[39m%s\u001b[39;00m\u001b[39m'\u001b[39m\u001b[39m\"\u001b[39m\n",
      "File \u001b[1;32mc:\\Users\\Himanshu\\anaconda3\\lib\\site-packages\\docx\\opc\\package.py:128\u001b[0m, in \u001b[0;36mOpcPackage.open\u001b[1;34m(cls, pkg_file)\u001b[0m\n\u001b[0;32m    122\u001b[0m \u001b[39m@classmethod\u001b[39m\n\u001b[0;32m    123\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39mopen\u001b[39m(\u001b[39mcls\u001b[39m, pkg_file):\n\u001b[0;32m    124\u001b[0m     \u001b[39m\"\"\"\u001b[39;00m\n\u001b[0;32m    125\u001b[0m \u001b[39m    Return an |OpcPackage| instance loaded with the contents of\u001b[39;00m\n\u001b[0;32m    126\u001b[0m \u001b[39m    *pkg_file*.\u001b[39;00m\n\u001b[0;32m    127\u001b[0m \u001b[39m    \"\"\"\u001b[39;00m\n\u001b[1;32m--> 128\u001b[0m     pkg_reader \u001b[39m=\u001b[39m PackageReader\u001b[39m.\u001b[39;49mfrom_file(pkg_file)\n\u001b[0;32m    129\u001b[0m     package \u001b[39m=\u001b[39m \u001b[39mcls\u001b[39m()\n\u001b[0;32m    130\u001b[0m     Unmarshaller\u001b[39m.\u001b[39munmarshal(pkg_reader, package, PartFactory)\n",
      "File \u001b[1;32mc:\\Users\\Himanshu\\anaconda3\\lib\\site-packages\\docx\\opc\\pkgreader.py:32\u001b[0m, in \u001b[0;36mPackageReader.from_file\u001b[1;34m(pkg_file)\u001b[0m\n\u001b[0;32m     27\u001b[0m \u001b[39m@staticmethod\u001b[39m\n\u001b[0;32m     28\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39mfrom_file\u001b[39m(pkg_file):\n\u001b[0;32m     29\u001b[0m     \u001b[39m\"\"\"\u001b[39;00m\n\u001b[0;32m     30\u001b[0m \u001b[39m    Return a |PackageReader| instance loaded with contents of *pkg_file*.\u001b[39;00m\n\u001b[0;32m     31\u001b[0m \u001b[39m    \"\"\"\u001b[39;00m\n\u001b[1;32m---> 32\u001b[0m     phys_reader \u001b[39m=\u001b[39m PhysPkgReader(pkg_file)\n\u001b[0;32m     33\u001b[0m     content_types \u001b[39m=\u001b[39m _ContentTypeMap\u001b[39m.\u001b[39mfrom_xml(phys_reader\u001b[39m.\u001b[39mcontent_types_xml)\n\u001b[0;32m     34\u001b[0m     pkg_srels \u001b[39m=\u001b[39m PackageReader\u001b[39m.\u001b[39m_srels_for(phys_reader, PACKAGE_URI)\n",
      "File \u001b[1;32mc:\\Users\\Himanshu\\anaconda3\\lib\\site-packages\\docx\\opc\\phys_pkg.py:30\u001b[0m, in \u001b[0;36mPhysPkgReader.__new__\u001b[1;34m(cls, pkg_file)\u001b[0m\n\u001b[0;32m     28\u001b[0m         reader_cls \u001b[39m=\u001b[39m _ZipPkgReader\n\u001b[0;32m     29\u001b[0m     \u001b[39melse\u001b[39;00m:\n\u001b[1;32m---> 30\u001b[0m         \u001b[39mraise\u001b[39;00m PackageNotFoundError(\n\u001b[0;32m     31\u001b[0m             \u001b[39m\"\u001b[39m\u001b[39mPackage not found at \u001b[39m\u001b[39m'\u001b[39m\u001b[39m%s\u001b[39;00m\u001b[39m'\u001b[39m\u001b[39m\"\u001b[39m \u001b[39m%\u001b[39m pkg_file\n\u001b[0;32m     32\u001b[0m         )\n\u001b[0;32m     33\u001b[0m \u001b[39melse\u001b[39;00m:  \u001b[39m# assume it's a stream and pass it to Zip reader to sort out\u001b[39;00m\n\u001b[0;32m     34\u001b[0m     reader_cls \u001b[39m=\u001b[39m _ZipPkgReader\n",
      "\u001b[1;31mPackageNotFoundError\u001b[0m: Package not found at 'e:\\Usecases\\Webscrape\\Download\\2021-11-05-PBAC-Web-Outcomes.docx'"
     ]
    }
   ],
   "source": [
    "import os\n",
    "doc_path = os.path.abspath('./Download/2021-11-05-PBAC-Web-Outcomes.docx')\n",
    "read_table_from_word_doc(doc_path)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "base",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.8"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
